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 INTRODUCTION 
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INTRODUCTION 
The present work was funded by “PON research and innovation Industrial PhD program” on a 
project titled “Understanding the relationship between normal function and aberrant aggrega-
tion: the case of Ataxin-3”. The main focus of the project is to investigate molecular mecha-
nisms involved in Spinocerebellar Ataxia type 3 (SCA3), a neurodegenerative pathology be-
longing to the group of polyglutamine (polyQ) neurodegenerative diseases which are caused by 
the expansion of the polyQ tract in the corresponding proteins. The expanded proteins are typ-
ically found to accumulate in intra-nuclear aggregates which are involved in neurodegeneration. 
Although a large number of studies have approached to the pathogenesis of these diseases, 
many important questions still remain open and suitable therapies are not developed yet. In 
particular, the aberrant aggregation of Ataxin-3 (Atx3) constitutes the fundamental basis of the 
SCA3 disease and the search of suitable molecules able to inhibit its supramolecular assembly 
is believed to be an efficient therapeutic strategy for this pathology.  
Atx3 is a ubiquitin hydrolase involved in the protein degradation system in cell, able to bind 
and cleave specific polyubiquitin chains, and it was chosen as a model for this study as it is the 
smallest protein involved in polyQ pathologies. In this work the hypothesis that the interaction 
of Atx3 with polyubiquitin chains may exert a protective role against aggregation has been 
investigated, based on the idea that the natural binders involved in the physiological function 
of the target proteins may stabilise their native structure. If this is verified it will constitute a 
concrete basis to develop therapeutic molecules, such as mimetic-peptides derived from Ubiq-
uitin (Ub) able to modulate the aberrant aggregation process of Atx3. 
Due to the complexity of the system in analysis and of the Atx3 aggregation process, a multi-
plexed experimental approach was developed, based on molecular biology methods and spec-
troscopic techniques, that allows observing different aspects of the phenomenon under investi-
gation both in-vitro and in cellular environment. 
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1 State of the Art 
1.1 Protein aggregation 
Proteins are essential elements for the life of organisms, and their extraordinary diversity and 
functional versatility is determined by the large number of conformations they can acquire[1]. 
The process by which a polypeptide chain reaches its unique and active three-dimensional con-
formation is called “Protein folding” which is among the most important and complex reaction 
in biology[2][3]. After being produced by ribosomes, proteins must fold to their functional na-
tive state and in most of the cases undergo folding and unfolding (at least partial) during their 
lifetime[4]. 
Classically the description of folding is based on the idea that all the information needed for a 
protein to reach the correct three-dimensional conformation is contained in the amino acid se-
quence. Based on this idea, the stability of a protein and the protein folding pathways are gen-
erally described by means of a funnel shaped free energy landscape[5]. The shape of the energy 
landscape surface depends on the amino acid sequence of the protein and on the interactions 
with the environment[3]. Each point on the surface describes all the accessible conformations 
that a polypeptide chain can adopt going through many independent pathways involving inter-
mediate states that lead to the protein native state, which represents the minimum of the folding 
funnel. The failure of protein folding may lead to misfolded conformations, and as a conse-
quence non-native contact may be formed. The incorrectly folded molecules may then access 
intra-molecular contacts and interact with other molecules leading to the formation of disor-
dered or highly ordered aggregates[6]. The path leading to aggregation is considered as an al-
ternative route, acting in competition with the folding process, and it may depends on several 
factors including amino acid sequence, temperature and solution conditions such as pH and 
ionic strength[7]. In this context, the energy landscape can be extended to a multi-protein sys-
tem where both inter-molecular and intra-molecular contacts are considered (Fig. 1.1). The re-
sulting supramolecular aggregates present different structures and morphologies ranging from 
amorphous structures to highly organized amyloids. Amorphous aggregates are mostly made 
up of disordered polypeptides chains, without defined shape or structure[8]; oligomers are small 
globular aggregates (less than 50 nm) formed by a low number of partially unfolded units (usu-
ally less than 50)[9]; amyloid fibrils, now recognised as the most stable state that a polypeptide 
chain can adopt[10], are elongated ordered protein aggregates characterised by a highly orga-
nized hydrogen-bonded structure, independent on the protein they are made of, which gives 
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them a unique kinetic stability[11]. In particular, they are stabilized by a common core cross‐
β‐sheet structure in which β‐sheets run parallel to the fibril axis[6][12]. 
 
Figure 1.1: Energy landscape for folding and aggregation pathways of a polypeptide chain in a multiprotein energy 
surface. Figure adapted from [7]. Local minima represent the ensembles of unfolded and intermediate states. A 
deep minimum is assigned to the native state, while the thermodynamically most stable structure of the protein is 
in the amyloid fibril. 
Although recent findings have lighted on that amyloid fibrils may have functional roles[13], 
they are of great interest as their formation has been implicated in the aetiology of a large variety 
of human diseases, including neurodegenerative disorders such as polyglutamine diseases 
(polyQ), Alzheimer's disease and Parkinson's disease. The understanding of the processes that 
lead to the formation of amyloid fibrils is, therefore, of crucial importance to identify possible 
therapeutic strategy of intervention. 
Protein association processes are intrinsically complex phenomena which may implicate mul-
tiple interconnected mechanisms, such as protein conformational changes and inter-molecular 
bonds formation involving single residues, specific regions or the whole molecule, nucleation 
mechanisms, solution-demixing, and growth of aggregates. All these mechanisms are intercon-
nected in different rates and their occurrence and extension is regulated by external condi-
tions[14][15]. 
In this respect, aggregation processes involve protein molecules both on a microscopic scale as 
single proteins undergo structural and conformational changes, and on a macroscopic scale 
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since a large number of molecules are involved in inter-molecular bonding and collective inter-
actions[15]. The driving forces for aggregation are the dominant interactions that regulate pro-
tein folding: the hydrophobic interactions contribute to the inter-molecular association of the 
intermediate structures, while polar interactions essentially contribute to the inter-molecular 
hydrogen bonds substantiating the cross--structure that constitutes amyloid fibrils[16]. 
Several studies indicate the possibility of the existence of general physical principles that gov-
ern protein aggregation and supramolecular structure formation, and several models for amy-
loids formation have been proposed[17]. Amyloid formation mainly occurs through nucleation 
and growth mechanisms, including primary and secondary nucleation pathways[18][19][20]. 
Other mechanisms include initial micelle formation[21], conformational conversion[22][23] 
and filament–filament association[24]. Protein aggregation through non-nucleated process have 
been also observed[25][26][15][27]. Although non exhaustive, a schematic representation of 
the protein self‐assembly into different species is reported in Fig. 1.2. 
 
Figure 1.2: Schematic representation of protein aggregation pathways. Figure adapted from [28]. All aggregation 
pathways are generated through the formation of multiple association-prone monomeric forms. The aggregation 
reaction may generate amorphous aggregates, different soluble oligomers with diverse morphologies, and mor-
phologically-divergent amyloid fibrils. 
1.2 Neurodegenerative diseases 
Neurodegenerative diseases are pathologies of the central nervous system involving dysfunc-
tion or progressive death of neurons cells in specific brain regions. These group of incurable 
diseases include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, fron-
totemporal dementia, prion diseases, and polyQ diseases such as, Huntington’s disease and 
spinocerebellar ataxias. Generally, the symptoms for these pathologies include cognitive 
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deficits, loss of memory, motor impairments and psychological and behavioural disorders with 
severe progression[29][30]. Although these diseases are different for transmission, clinical and 
progression, they share common features, such as old age-onset and the accumulation of aggre-
gated proteins in the brain[31]. Coherently with the last evidence, it has been extensively 
demonstrated that protein aggregation processes are implied in these pathologies and may in-
duce cellular toxicity[32][33][34][35]. A growing consensus exists in considering a continuum 
of aggregates species formed during supramolecular assembly, rather than a single uniform 
species as main toxicity effector[36]. Evidences have emerged suggesting that these species 
share both common structural features and the ability to permeabilise cell membranes, poten-
tially initiating multiple processes leading to cell impairment and death critical in the onset and 
progression of disease[37][38]. In particular, both fibrils and oligomers formed during the ag-
gregation pathways have been found to induce toxicity, but notwithstanding the large number 
of studies the role of toxic species and the equilibria between oligomers and fibrils remains to 
be clarified, both in terms of assembly of oligomers into fibrils and potential dissolution of 
fibrils into oligomers. Many controversial results exist in literature and no clear conclusions 
can be drawn due to the great variety and heterogeneity of different experimentally observed 
states. 
In this context, the investigation of the origin of high impact neurodegenerative disorders can-
not be separated from an accurate description of the inter- and intra-molecular interactions in-
volved in the formation of amyloid aggregates. This is of fundamental importance because the 
increased understanding of the factors that control supramolecular assembly, resulting species 
and their toxicity, can allow the development of new therapeutic strategies. 
1.3 Polyglutamine disease 
PolyQ disorders are dominant late-onset genetic neurodegenerative disorders accompanied by 
progressive death of neuronal cells in distinct regions of the brain, with consequent neurological 
symptoms such as cognitive impairment and motor disorder, depending on the affected brain 
regions[39][40]. Even if each polyQ disease has a specific symptomatology, and present neu-
ronal cells damage in specific brain regions, the neurotoxicity of all these diseases always cor-
relates with the expansion of poly-CAG repeats in the gene encoding for the causative protein 
of the pathology, which as consequence will contains a long consecutive glutamine (Q) tract in 
its sequence[41]. Furthermore, the length of the expansion correlates with the age of onset of 
the disease and with the severity of the symptoms[42][43]. 
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Nine neurodegenerative disorders belong to polyQ diseases family: Spinocerebellar Ataxia type 
1, 2, 3, 6, 7 and 17 (SCAs), Huntington's disease (HD), Dentatorubral Pallidoluysian Atrophy 
(DRPLA), and Spinal Bulbar Muscular Atrophy X-linked type 1 (SMAX1/SBMA). These pa-
thologies are dominantly inherited disorders, except for SBMA which is an X-linked disorder. 
A list of the nine pathologies belonging to polyQ diseases is reported in Table 1.1, together with 
relative causative proteins, and the position of the polyQ tract in each protein. The proteins 
involved in the aetiology of these diseases, differ in size, cellular localization and biological 
function, but they have in common an expansion of their polyQ trait, suggesting that the expan-
sion of this trait has an important role in the pathogenetic mechanism of the disease, although 
the details of the molecular mechanism are not yet well understood and are largely debated[39]. 
Toxic effects may be directly caused by aberrant supramolecular assemblies formed by the 
causative proteins, or may be an indirect effect of these assemblies due to their ability in se-
questering functional proteins hindering their physiological function[31]. Moreover, the in-
creased tendency to aggregate of causative proteins may alter their binding to biological part-
ners and thus leading to pathology[44]. 
 
Table 1.1: PolyQ diseases and related causative proteins. The range of polyQ expansions found for each pathology 
is also indicated. Highlighted in yellow, the region that contains the polyQ tract for each protein. Table adapted 
from [45]. 
Several studies have shown that proteins containing expanded polyQ tract may undergo con-
formational changes leading to β-sheet rich structure in the monomeric state, which assembles 
into oligomers and insoluble aggregates with amyloid fibrillar structures, potentially leading to 
accumulation as intracellular inclusions[46]. Among others, two models explaining polyQ 
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aggregation mechanisms received larger consensus in the scientific community: one is the nu-
cleation-elongation model, where a monomer is in rapid equilibrium between un unfolded state 
and a thermodynamically unfavourable -structured state. This acts as a nucleus and works as 
a template to add other monomers, forming an elongated -structure fibrils[47]. The other 
model is the association-conformational conversion model, that consists in the association of 
soluble oligomers, driven by hydrophobic interactions between disordered monomers, followed 
by further conformational rearrangements resulting in insoluble fibrils[41][48]. Both models 
consider the reactivity of the only polyQ trait, and are based on the idea that long polyQ tracts 
are highly reactive and readily undergo to misfolding and aggregation, resulting in an assembly 
of its host protein into insoluble aggregates with β-sheet rich amyloid fibrillar structures. How-
ever, it was demonstrated that polyQ flanking domains can modulate the aggregation process. 
The result is a two stages aggregation process, where conformational changes and early oli-
gomerization are mediated by the polyQ-flanking domain, while the formation of SDS-insolu-
ble fibrils, is polyQ-dependent[49][50][51]. Moreover, flaking polyQ domains play a crucial 
role in the formation of intermediaries species during aggregation, that are considered more 
toxic than insoluble aggregates in nuclear inclusions[52][53]. The scenario is further compli-
cated by several studies reporting that proteolytic cleavage of polyQ proteins is required for 
inclusion formation in the brain[54][55][56]. 
In this intricate scenario, aggregation mechanisms of proteins implied in polyQ pathologies and 
how they are involved in neurodegeneration is not fully understood yet. The experimental con-
ditions of related studies are critical in modulating observed aggregation pathways, newly 
formed oligomeric intermediates, and toxic effects. Since the aggregation process is thought to 
be a crucial event in the common pathogenic cascade of the polyQ diseases, finding strategies 
to suppress or delay it is of utmost importance for the development of therapies to cure patients 
affected by these diseases. Many approaches have been proposed based on small chemical mol-
ecules or peptides which inhibit the aggregation process by specifically binding to the expanded 
polyQ tract or specifically targeting the causative protein, but none of them has been successful 
so far[57]. 
In this thesis, aggregation mechanisms of Ataxin-3 (Atx3) and possible strategies for inhibiting 
its supramolecular assembly were investigated. Atx3 is responsible of Spinocerebellar Ataxia 
type 3 (SCA3), the most common among ataxias, and it is the smallest causative protein within 
polyQ diseases family[58]. Atx3 represents a good model for studying different aspects of 
polyQ diseases as its small size and its modular structure, containing a globular domain and an 
intrinsically disordered flexible tail, may allow studies on selected features of the aggregation 
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process. For instance, it is possible to highlight the role of different regions in modulating ag-
gregation, thus giving information on possible strategies to stabilise the native state. 
1.4 Spinocerebellar Ataxia type 3 
SCA3, also known as Machado–Joseph disease (MJD), is the most common inherited spino-
cerebellar ataxia belonging to the group of polyQ neurodegenerative diseases. This disease pre-
sents the common pathogenic characteristics of polyQ diseases and is caused by Atx3, a protein 
encoded by a gene mapped in the 14q32.1 chromosome region[59]. The number of glutamines 
in the normal and expanded polyQ tract of Atx3 ranges between 12-50 and 55-84, respec-
tively[60][61]. 
Clinical manifestations of SCA3 include cerebellar ataxia, progressive external ophthalmople-
gia, dysarthria, dysphagia, pyramidal signs, dystonia, rigidity, and distal muscle atrophies[59]. 
The first identification of SCA3 occurred in four families of Azorean ancestry and described as 
four distinct pathologies, that subsequently were recognized as variations of the same disorder 
defined as Machado-Joseph disease[62][63][64][65][66]. Type 1 begins early in life, before age 
20, and it is characterized by prominent pyramidal signs (rigidity and spasticity) and extrapy-
ramidal features (bradykinesia and dystonia) as well as ataxia[63][67]. Type 2, the most com-
mon type, has an intermediate age onset (20–50 years) with cerebellar ataxia, progressive ex-
ternal ophthalmoplegia and pyramidal signs[68]. Type 3 has a later onset (40–75 years) and it 
is characterized by peripheral signs such as motor neuronopathy and muscle atrophy together 
with ataxia[69]. Type 4, the rarest type, is characterized by parkinsonism associated with other 
core clinical features[65][70]. More recently, a type 5 was proposed for rare cases presenting 
pure spastic paraplegia[71]. 
Currently, SCA3 disease still remains incurable. Therapeutic approaches have been investi-
gated to inhibit Atx3 protein expression, using antisense oligonucleotides mRNA or duplex 
RNA able to slowing down the progression of the disease[72]. The length of the polyQ tracts 
certainly affects the success of this approach, in fact the longer polyQ tracts are able to form 
hairpin structures that could interfere with the success of gene therapy[73]. Other therapeutic 
approaches involve the use of molecular chaperones targeting expanded Atx3 to suppress its 
misfolding[74][75], or the induction of expanded Atx3 autophagy to reduce its deleterious ef-
fects[76], or the transcriptional deregulation of Atx3 gene[77]. The approach considered in this 
thesis, is based on the hypothesis that peptide-mimetics compounds derived from Atx3 natural 
interactors, may be able to interact with Atx3 and modulate its aggregation propensity. 
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1.5 Ataxin-3 structure and function 
Atx3 is a de-ubiquitinating enzyme (DUB) ubiquitously expressed in human tissues, and be-
longing to the family of cysteine proteases. It is a multidomain protein and its structure consists 
of an N-terminal catalytic domain called Josephin domain (Jos, amino acid region 1-182), and 
a C-terminal region that consists of the polyQ tract and 2 or 3 Ubiquitin interactive motifs 
(UIMs) (Fig. 1.3)[78]. The Josephin domain also contains two nuclear exporting signal (NES) 
motifs, necessary to efficiently retain Atx3 in the cytoplasm, while a nuclear localization se-
quence (NLS) is situated at the C-terminal tail of full-length Atx3 before the polyQ region, and 
allows Atx3 to act also as a transcriptional regulation player. NLS most likely allows translo-
cation to the nucleus also of C-terminal fragments generated by cleavage of expanded Atx3, 
which lead to the formation of intranuclear aggregates[79]. 
 
Figure. 1.3: Schematic representation of domains organization of Atx3 protein. Atx3 has a molecular weight of 
about 42KDa. The healthy isoform, generally contains a range of 8-50 glutamine residues, while the pathological 
isoforms contain a range of 55-84 glutamine residues[60]. 
Atx3, as DUB enzyme, mainly recognizes K48- and K63-linked polyubiquitin chains (polyUb), 
and cleaves them thanks to the catalytic triad formed by Cystein 14, Histidine 119 and Aspara-
gine 134 residues[50][80][81][82][83]. The catalytic triad is flanked and supported by two 
Ubiquitin-binding sites within the Josephin domain, Site 1 and Site 2. Site 1 is close to the 
catalytic site, and it is important for polyUb cleavage activity since it binds a Ubiquitin (Ub) 
moiety and helps its positioning into the catalytic site[50]. Site 2 is responsible for ubiquitin-
chain linkage preference, and interacts with N-terminal domain of the Ubiquitin-like domain of 
HHR23B, a protein involved in the ubiquitin proteasome pathway as well as Atx3[50][82]. The 
NMR solution structure of the Josephin domain is reported in Figure 1.4, with highlighted the 
catalytic triad (Cys 14, His119 and Asn 134), Site 1 (Ile77, Leu91, Trp120, and Phe163), and 
Site 2 (Tyr27, Phe28, and Trp87)[82]. 
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Figure 1.4: NMR solution structure of Josephin domain (PDB ID: 1yzb)[50]. The left and rigth structures are 
related by a rotation of 180° around a vertical axis. Josephin shows a predominant α-helical fold that is typical of 
cysteine proteases. The catalytic triad is highlighted in blue, while the residues of Site 1 and Site 2 are highlighted 
in orange and in cyan, respectively. 
The presence of different Ub binding sites in Atx3 sequence, and its ability to bind and cleave 
polyubiquitinated proteins, demonstrates that the principal function of Atx3 in cell deals with 
the cellular protein quality control system, in particular, with the ubiquitin proteasome system 
(UPS)[80]. Indeed, it was shown that where Atx3 expression is suppressed or altered in animal 
models, an accumulation of polyubiquitinated proteins occurs[84][85]. Moreover, several evi-
dences show that Atx3 interacts with proteins belonging to the UPS system, such as 
p97/valosin-containing protein (VCP)[86][87][88], and several E3 Ubiquitin ligases[89].  
Atx3, specifically binds and cleaves K48-linked, K63-linked and mixed K48-, K63-linked 
polyUb chains attached to target proteins as post-translational modification (PTM)[50][90]. 
K48-linked poly-ubiquitination PTM affects predominantly proteins for proteasomal degrada-
tion, whereas K63-linked poly-ubiquitination PTM seems to regulate protein function, subcel-
lular localization and protein–protein interactions[91]. 
Although, the main biological role of Atx3 correlates with the regulation of protein degradation, 
it has also a role in transcriptional regulation. Indeed, Atx3 binds DNA and interacts with tran-
scription regulators, such as cAMP-response element binding (CREB)- binding protein 
(CREBBP), inhibiting the CREB-mediated transcription pathway[92]. Moreover, Atx3 
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modulates transcription by interacting with several transcription factors, such as the Forkhead 
box O4 peptide (FOXO4), Wilm’s tumor protein 1 (WT1), and the TATA box protein (TBP) 
belonging to the Transcription factor II D complex  (TFIID)[93]. Atx3 also promotes the 
deacetylation of histones, by its binding to specific chromatin regions of the metalloproteinase-
2 (MMP2) gene promoter, and recruiting the histone deacetylase 3 (HDAC3) and the nuclear 
receptor co-repressor 1 (NCOR1) to these regions[93]. 
1.6 Ataxin-3 aggregation 
Atx3 shows an intrinsic propensity to aggregate in vitro under native conditions[51].  Both wild 
type Atx3 and expanded Atx3, and also the isolated Josephin domain, show tendency to aggre-
gation and are able to form amyloid-like fibrils[94][95][96][97]. The first accredited model for 
Atx3 aggregation process consisted in a nucleation-dependent process (Fig. 1.5). In this model, 
the first step involves the self-association of Josephin domain, able to form SDS-soluble aggre-
gates[94]. This step does not involve the polyQ tract, and the kinetics of aggregation is charac-
terized by a nucleation-dependent process[95][98]. The second step involves the polyQ tract, 
responsible for a faster aggregation kinetics and for the formation of SDS-insoluble fibrils[95]. 
Further evidences highlighted that self-cleavage propensity of Atx3 may cause seeds formation 
favouring aggregation processes[99]. More recently, it has been found that not only the Jose-
phin domain, but also the partially disordered region between Josephin domain and polyQ trait 
(182–291) plays a key role in the aggregation process and in developing the disease[100]. 
 
Figure 1.5: Two-step model of Atx3 aggregation. The first step of Atx3 self-assembly, independent on polyQ 
tract, is triggered by the Josephin domain. The resulting oligomers and small protofibrils are sensitive to SDS. The 
second step, dependent on the polyQ expansion, leads to the formation of mature and SDS-resistant Atx3 fibrils. 
Figure adapted from [94]. 
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Although the expansion of the polyQ remains to be considered among the main causes of the 
onset of polyQ-related degenerative diseases, it is now well recognized that protein context 
greatly influences polyQ protein aggregation. Misfolding of polyQ flanking domains seems to 
have a key role in Atx3 aggregation process, promoting fragmentation and formation of oligo-
meric species, considered more toxic than the mature fibrils[101][102]. These observations sug-
gest that new therapeutic approaches may be generated by targeting flanking domains rather 
than targeting the polyQ region. 
The experimental design of this thesis work, was directed at analysing aggregation process of 
Atx3 using recombinant proteins and spectroscopic techniques. This was mainly aimed at in-
vestigating the possibility of modulating supramolecular assembly using Atx3 physiological 
binding partners, such as ubiquitin chains and Ub-derived peptide-mimetics compounds. Atx3 
and Ub stability were then investigated in order to evaluate the hypothesis that the interaction 
between polyUb and Atx3 may have effects on Atx3 stability and/or interferes with the aggre-
gation process. Selected models of Atx3 were engineered in order to compare aggregation pro-
cesses of non-expanded Atx3, expanded Atx3, and Josephin domain in specific conditions. 
Atx3 proteins were mutated to obtain the substitution of the cysteine residue in position 14 with 
an alanine residue (C14A). This mutation inactivates the protein catalytic site, and as a conse-
quence reduces self-cleavage activity of Atx3[99]. This was intended to isolate “seeding” which 
may trigger heterogeneous aggregation mechanisms. Furthermore, the point mutation C14A, 
introduced also in Josephin, inhibits the catalytic activity against polyUb chains giving the pos-
sibility to study the interaction. The conformational stability of non-expanded and expanded 
Atx3 was studied in vitro, revealing no differences in supramolecular assembly at different 
polyQ length. These results were also confirmed in in-cell studies. These experiments were 
performed to establish suitable conditions to analyse the effects of polyUb on the selected ag-
gregation processes. The effects of natural binders of Atx3 on its aggregation propensity was 
previously analysed using isolated Josephin domain and mUb, and resulted in a decrease of 
Atx3 aggregation propensity and in a slowdown of the aggregation kinetics[103]. Based on this 
evidence, and on the fact that Atx3 presents a higher affinity for polyUb chains than for mUb, 
the synthesis of triUb chains was performed and its effect on the Josephin domain aggregation 
process was evaluated. The results clearly indicated that aggregation process is successfully 
reduced, confirming that the design of Ub-derived peptide-mimetics compounds can be a good 
therapeutic strategy. 
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2 Material and Methods 
2.1 Recombinant Proteins Production 
Non expanded Ataxin-3 (Atx3-Q14), expanded Ataxin-3 (Atx3-Q54) and Josephin domain 
(Jos) used in this experimental work have been prepared recombinantly. Recombinant proteins 
are important tools for studying biological processes and provide important findings in biomed-
ical research. The production of recombinant proteins involves several steps and techniques and 
allows to have samples with high grade of purity (above 90%) suitable for in vitro studies. The 
first step generally consists in isolating the DNA sequence encoding for the protein of interest, 
cDNA, and amplifying it by Polymerase Chain Reaction (PCR). This is a widely used molecular 
biology technique developed in 1983 by Kary Mullis, which allows exponential enzymatic am-
plification of small amount of DNA sequences by a series of repeated temperature changes, 
called thermal cycles[104]. Once the cDNA is isolated and amplified, it is inserted into an ex-
pression vector which is a plasmid or a virus used to introduce the cDNA into a host cell, and 
can command the protein synthesis machinery of the host cell to produce the protein encoded 
by the cDNA. For this purpose, expression vectors have to provide an inducible promoter acti-
vable by a chemical inducer, the origin of replication, the correct translation initiation sequence 
and a selection marker (generally an antibiotic resistance gene)[105][106]. Furthermore, ex-
pression vectors are often modified in order to introduce a nucleotide sequence encoding for a 
tag or a fused protein upstream or downstream the sequence encoding for the protein of interest. 
This facilitates the purification or detection of the final protein product and/or enhances recom-
binant protein productivity[106]. The method of insertion of the cDNA into the vector depends 
on the chosen cloning strategy, such as restriction enzymes-based cloning, TA-cloning, 
TOPOTM-cloning, ligation independent cloning (LIC) or cloning via recombination (Gate-
wayTM, CreatorTM)[107][108][109][110][111]. The expression vector containing the cDNA 
is then transferred, by electroporation or by chemical treatment, into the host cell which can be 
prokaryotic or eukaryotic. The choice of the host is made to ensure the maximal amount of 
expression, the proper folding of the product, and to sustain the protein in the intact and func-
tional state[112]. Vector-modified host cells are then cultured in the appropriate culture me-
dium, and protein expression is induced at a specific stage of growth by adding the chemical 
inducer of the vector promoter. Culturing conditions are quite standard for the chosen host cell, 
while induction conditions (temperature, time and inducer concentration) are optimized to guar-
antee the maximum protein production[113]. The recombinant protein is released by the cells 
to the culture medium or kept inside the cells and recovered by cells lysis, and purified generally 
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by liquid chromatography methods such as ionic-exchange and/or affinity chromatography. A 
final step of size exclusion chromatography is also often performed to gain high grade purity 
protein samples suitable for structural and biophysical studies[112]. 
2.1.1 Recombinant Atx3-Q14, Atx3-Q54 and Jos 
A successful expression strategy consists of the production of proteins with functional and bi-
ochemical characteristics corresponding to the biological and native state. The prokaryotic ex-
pression system Escherichia Coli (E. coli), the most widely used[114], resulted suitable for the 
production of the three recombinant proteins used in this experimental work: Atx3-Q14, Atx3-
Q54, and Jos (proteins sequences are reported in Annex I). In particular, E. Coli BL21 (DE3) 
pLysS strain was chosen for reducing background expression of the proteins before induction 
that might result toxic for the cell[105]. The bacterial expression vectors were all pET (Plasmid 
for Expression by T7 RNA polymerase)[115] containing the T7 bacteriophage promoter and 
the gene for the resistance to ampicillin antibiotic. They were provided by Dr C. Alfano from 
Ri.MED Foundation, and engineered in order to obtain the recombinant proteins fused to a 
poly-histidine tag (6xHis-tag) which allowed protein purification by Immobilized Metal Affin-
ity Chromatography (IMAC)[116]. To enhance the protein solubility and facilitate the purifi-
cation, expression vectors for Atx3-Q14 and Atx3-Q54 were also modified in order to generate 
the recombinant proteins fused with the highly soluble Maltose Binding Protein (MBP)[117]. 
In all the three vectors, the sequence encoding for the cleavage site of Tobacco Etch Virus 
(TEV) protease was also inserted downstream the sequencing encoding for the 6xHis-tag[118]. 
This allowed the enzymatic removal of the MBP region and/or the 6xHis-tag from the purified 
recombinant products since they might interfere with the biophysical and structural stud-
ies[119][120]. Moreover, all constructs had the point mutation C14A in order to inactivate their 
catalytic sites, avoiding the auto-cleavage propensity of full length Atx3[99], and the cleavage 
of polyUb chains when biophysical studies were performed on both Jos/polyUb and 
Atx3/polyUb complexes. Domains organization of the three constructs is reported in Fig. 2.1. 
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Figure 2.1: a) Domains organization of recombinant Jos: N-terminal 6xHis-tag (dark green), the site recognized 
by TEV protease (pink) and Jos catalytic domain (violet); b) Domains organization of Atx3-Q14: Maltose binding 
protein (MBP) (orange), 6xHis-tag (dark green), the site recognized by TEV protease (pink), Jos domain (violet), 
3 Ubiquitin interactive motifs (UIM) (green) and polyQ tract with Q14 (light blue); c) Domains organization of 
Atx3-Q54: MBP (orange), 6xHis-tag (dark green), the site recognized by TEV protease (pink), Jos domain (violet), 
3 UIMs (green) and polyQ tract with Q54 (light blue). Point mutation C14A, which inactivates the catalytic pro-
prieties of all the three constructs, is also indicated. 
In details, for the production of each of the three constructs, competent E. Coli BL21 (DE3) 
pLysS cells were transformed with plasmids using the standard heat shock protocol[121]. 
Transformed cells were then cultured in Luria Bertani medium (LB) supplemented with 50 
g/ml of ampicillin, at 37°C until the culture reached an optical density at 600nm of 0.6. Pro-
teins expression was then induced by adding Isopropil-β-D-1-tiogalattopiranoside (IPTG) 
which allows the expression of the T7 RNA polymerase by binding the protein responsible for 
the repression of its transcription (Lac operon repressor protein)[122]. IPTG was used at a final 
concentration of 0.5mM, and expression was carried out for 4 hours at 37°C under shaking. 
Harvested cells were resuspended in 20 mM Tris-HCl, 300 mM NaCl, 5% Glycerol, 1mM DTT, 
5mM MgCl2, pH 7.2, supplemented with 0.5mg/ml Lysozyme, 10µg/ml DNase I, and Complete 
EDTA-free protease inhibitor cocktail, then lysed by sonication. Recombinant proteins were 
purified from the soluble fractions of the cell lysates by IMAC using ready-to-use HisTrap FF 
crude column pre-packed with Nickel-Sepharose resin. His-tagged proteins were retained by 
the column, thanks to the histidine residues that readily coordinate the Nickel ions immobilized 
on the column resin. Proteins elution was performed fluxing through the column 20 mM Tris-
HCl, 300 mM NaCl, 500 mM imidazole, 5% Glycerol, 1mM DTT, pH 7.2 since imidazole 
competes with the His-tag for binding to the Nickel-charged resin. Before elution, 20 column 
volumes (CV) of 20 mM Tris-HCl, 1M NaCl, 5% Glycerol, 1mM DTT, pH 7.2 were passed 
through the column to wash out unspecific-bounded components. Eluted fractions were 
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collected and analysed by denaturing Sodium Dodecyl Sulphate – Poly-Acrylamide Gel Elec-
trophoresis (SDS-PAGE). Fractions containing the target protein were then pooled together and 
digested with TEV protease (TEVp) to remove the N-terminal tag. Digestion was performed 
while dialyzing the protein/TEVp mix in 20 mM Tris-HCl, 300 mM NaCl, 5% Glycerol, 1mM 
DTT, pH 7.2. TEVp:Protein 1:2 and 1:6 molar ratio were used for Atx3 isoforms and Jos, re-
spectively. Digested proteins were then separated from undigested protein, tags, and TEVp by 
IMAC using again a ready-to-use HisTrap FF crude column pre-packed with Nickel-Sepharose 
resin. Digested proteins were recovered from the flow through fraction as they lost the His-tag, 
and were subjected to a final step of Size Exclusion Chromatography (SEC)[123] using a Hi-
Load 26/600 Superdex 75 pg GE Helthcare column equilibrated with 20mM Na-phosphate, 
1mM TCEP, pH 6.5. SEC is widely used to separate proteins and polymers in solution by their 
size thanks to the size heterogeneity of the porous beads composing the column resin. Smaller 
solutes have access to more pores and are then retained for a longer period of time compared to 
larger solutes. In the present experimental work, the use of SEC as final purification step al-
lowed the removal of both protein aggregates and degradation products resulting in high grade 
purity proteins samples suitable for the biophysical studies later performed. 
In Figg. 2.2, 2.3 and 2.4 are reported the chromatography profiles and the SDS-PAGE results 
of Atx3-Q14, Atx3-Q54 and Jos, respectively. 
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Figure 2.2: Purification of Atx3-Q14: a) affinity chromatography profile of the first IMAC step performed on 
His-tagged protein. Left axis in blue indicate absorbance at 280nm, while right axis in dark red indicate % elution 
buffer. b) SDS-PAGE analysis related to a) fractions. c) affinity chromatography profile of the second IMAC step 
performed after His-tag removal. Left axis in blue indicate absorbance at 280nm, while right axis in dark red 
indicate % elution buffer, and d) SDS-PAGE analysis related to c) fractions. e) SEC profile and f) SDS-PAGE 
analysis performed on cleaved Atx3-Q14 as final purification step. Lanes 10-13 correspond to the purest fractions 
of peak P1 in SEC profile (F47-50) and have been used for aggregation kinetic experiments. 
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Figure 2.3: Purification of Atx3-Q54: a) affinity chromatography profile of the first IMAC step performed on 
His-tagged protein. Left axis in blue indicate absorbance at 280nm, while right axis in dark red indicate % elution 
buffer. b) SDS-PAGE analysis related to a) fractions. c) affinity chromatography profile of the second IMAC step 
performed after His-tag removal. Left axis in blue indicate absorbance at 280nm, while right axis in dark red 
indicate % elution buffer and d) SDS-PAGE analysis related to c) fractions. e) SEC profile and f) SDS-PAGE 
analysis performed on cleaved Atx3-Q54 as final purification step. Lanes 12-14 correspond to the purest fractions 
of peak P1 in SEC profile (F45-47) and have been used for aggregation kinetic experiments. 
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Figure 2.4:  Purification of Jos domain: a) affinity chromatography profile of the first IMAC step performed on 
His-tagged protein. Left axis in blue indicate absorbance at 280nm, while right axis in dark red indicate % elution 
buffer. b) SDS-PAGE analysis of affinity chromatography step performed after His-tag removal. c) SEC profile 
and d) SDS-PAGE analysis performed on cleaved Jos as a final step. All SEC fractions resulted high-grade pure 
and where all used for aggregation kinetic experiments. 
2.2 Ubiquitin samples 
As discussed in chapter 1, polyUb chains are natural partners of Atx3. In particular, Atx3 has a 
high affinity for K48-linked and K63-linked polyUb chains[82][90]. In this experimental work 
we produced K48-linked polyUb chains by enzymatic reaction, and investigated the effect of 
these chains on the aggregation process of Josephin domain. Free mono-Ub (mUb) samples 
were also used to investigate the general aggregation features of ubiquitin samples. 
2.2.1 mono-Ubiquitin samples preparation 
mUb samples were freshly prepared in solution just before each measurement. Protein powder 
was purchase from Sigma Aldrich, and dissolved in 20 mM sodium phosphate buffer, pH 6.5 
at different concentrations (0.5, 0.7 and 1.8 mg/ml) then filtered through 0.20 μm filters. Protein 
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concentration was spectrophotometrically determined using a molar extinction coefficient of 
1254 dm3mol-1cm-1 at 280 nm [124]. 
2.2.2 Enzymatic production of K48-linked tri-Ubiquitin samples 
The production of polyUb chains by enzymatic reaction was first developed by Pickart’s group, 
who prepared K48-linked di- and tetra-Ub chains for crystallographic studies starting from 
wild-type Ub[125]. Since then, the method was further optimized by several research groups to 
obtain multi milligram quantities of material required for biophysical and/or structural studies 
(reviewed in [126]). The formation of polyUb chains occurs through linkage between the lysine 
residue of one Ub monomer and the C-terminal glycine residue of another Ub monomer. The 
method is based on the formation in one reaction of Ub chains of different lengths, using the 
ubiquitin-activating enzyme (E1), and a specific ubiquitin-conjugating enzyme (E2). In detail, 
first, the C-terminal Gly residue of Ub is activated in an ATP-dependent process by E1, with 
the formation of ubiquitin adenylate, releasing PPi, then Ub binds a Cys residue of E1 forming 
a thiol-ester linkage, releasing AMP. In the second step, activated Ub is next transferred to an 
active Cys residue of E2 (Cdc34), that directly transfers Ub to a lysine 48 of successive Ub in 
order to obtain K48-linked polyUb chains, where ubiquitins are linked by an isopeptide bond 
between side chain of Lys 48 and the carboxyl group of Gly 76[127]. 
In this experimental work we produced K48-linked triUb chains using the enzymatic reaction 
described above. Components used to prepare K48-linked triUb samples are reported in Table 
2.1. Reagents were mixed together and incubated at room temperature for 2 hours. Reaction 
was then stopped by adding Dithiothreitol (DTT) at a final concentration of 50mM, and the mix 
was incubated on ice for 30 mins to release all E1- and E2-linked ubiquitin molecules. The 
mixture was then diluted 1:15 with 50 mM Sodium Acetate, pH 4.5 and loaded onto a 1ml pre-
packed cationic exchange chromatography Hitrap SP column. A linear gradient of 240 column 
volumes (CV) of 50 mM Sodium Acetate, 0.5 M NaCl, pH 4.5 was performed to separate the 
polyUb of different length. In Fig. 2.5 the SP chromatography profile of polyUb mix purifica-
tion and the respective SDS-PAGE are reported. 
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Component Final concentration 
E1  2M 
Cdc34  40M 
Wilde type mUb (from Sigma)  800M 
MgCl2/ATP                     10mM 
DTT                                        0.5mM 
10x reaction buffer 1x 
H2O  
Table 2.1: Components and concentrations used for enzymatic reaction for K48-linked triUb production. 
 
Figure 2.5: Purification of polyUb chains mixture: a) SP chromatography profile. Left axis in black absorbance 
at 280nm and red axis in green, % of elution buffer. b) SDS-PAGE of SP column fractions: Lane 1-9, correspond-
ing to peak P5, reveal the presence in the peak of both isolated mUb and a mix of mUb and diUb; Lane 10-13, 
corresponding to peak P4, reveal the presence in the peak of isolated diUb; Lane 14-18, corresponding to peak P3,  
reveal the presence in the peak of a mix of diUb and triUb; Lane 19-23, corresponding to peak P2, reveal the 
presence in the peak of isolated tri-Ub; Lane 24-27, corresponding to peak P1, reveal the presence in the peak of 
a mix of triUb and tetraUb. 
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In order to increase the yield of the preparation, and at the same time to obtain a final sample 
free of any aggregate, fractions from SP column containing a mix of diUb and triUb and those 
containing only triUb, were pooled together and further purified by SEC using HiLoad 16/600 
Superdex 75 pg GE Healthcare column, previously equilibrated in 20mM Na phosphate buffer 
with 1mM TCEP, pH 6.5. As shown in Fig 2.6, K48-linked triUb eluted as a well isolated peak 
and resulted in a high-grade purity sample suitable for biophysical studies. 
 
Figure 2.6: Final purification step of diUb and triUb mix: a) SEC profile, b) SDS-PAGE of SEC fractions. Lane 
1: marker; Lane 2: start; Lanes 3-16: fractions corresponding to peak P1, which reveal the presence of isolated 
triUb; Lane 17-21: fractions corresponding to peak P2, which reveal the presence of isolated diUb. 
2.3 Preparation of reference proteins 
In order to perform comparison measurements to evaluate the effect of UV exposure observed 
for Ub, two amyloidogenic proteins, Human Insulin and Aβ(1-40) peptide, were used. 
 The samples were freshly prepared before each measurement. Human Insulin powder (Sigma-
Aldrich) and Aβ(1-40)peptide (prepared as described in[128]), were dissolved in 20mM sodium 
phosphate buffer, pH 6.5. Protein concentration of Human insulin and Aβ(1-40) peptide were 
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estimated by means of absorbance measurements using a molar extinction of 1.067 cm-1 
(mg/ml)-1 at 276 nm[129], and of 1390 M−1 cm−1 at 276nm[130], respectively. 
Moreover, in order to obtain aggregates, 0.2 mg/ml Human insulin in 20 mM sodium phosphate 
buffer, pH 6.5, was incubated at 60°C stirring at 500 rpm for 24 hours, and 0.2 μM Aβ(1–40) 
in 20 mM sodium phosphate buffer, pH 6.5, was incubated at 37°C with stirring at 500 rpm for 
24 hours. 
2.4 Preparation of Jos/K48-linked triUb complex 
In order to study the effect of polyUb chains on the aggregation process of Atx3, Jos/K48-
linked triUb complex was prepared. Freshly purified recombinant Jos was incubated with puri-
fied K48-linked triUb, in a 1:1 molar ratio at room temperature for about 1 hour. The mixture 
was then separated by SEC, using a HiLoad 10/300 GL Increase 200 pg GE Helthcare column 
previously equilibrated in 20mM sodium phosphate buffer with 1mM TCEP, pH 6.5. As shown 
in Fig.2.7 a), the complex was eluted as an isolated peak and resulted in a high-grade purity 
sample. 
 
Figure 2.7: Purification of Jos/K48-linked triUb complex: a) SEC profile; b) SDS-PAGE analysis of SEC frac-
tions. The complex comes out of the column earlier as an isolated peak, while unbounded triUb elutes later. 
2.5 Spectroscopic Techniques 
In order to understand the molecular mechanisms underlying the supramolecular assembly of 
Atx3, and hopefully to find a strategy to prevent or interfere with them, thermal aggregation 
was induced in different Atx3 variants and kinetic measurements were performed and analysed. 
In particular, aggregation of Atx3-Q14 and Atx3-Q54 variants, free Jos and Jos/K48-linked 
triUb complex, were investigated. Aggregation was induced by high temperature (50°C) and 
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supramolecular assembly was analysed by multiple methods in a time resolved fashion to obtain 
complementary information on protein secondary structure, hydrophobicity, and protein native 
state stability[7][18]. The experimental platform was firstly developed and tested on the model 
protein Ub. Interestingly, the analysis of Ub aggregation kinetics at high temperature revealed 
that standard measurement methods may induce unwanted modifications in proteins which 
were identified as UV-light induced oxidation of tyrosine residues. Moreover, the same confor-
mational changes induced by UV exposure were also observed for Human Insulin and Amyloid 
(1-40) peptide, that instead Ub are able to form amyloid aggregates but as Ub do not contain 
Trp residues in their sequences [131][132][133]. 
Aggregation kinetics were investigated by varying systematically relevant physicochemical pa-
rameters, such as pH, protein concentration, temperature and ionic strength, as the comparison 
between them provide selective information on fundamental interactions regulating supramo-
lecular assembly[134]. In fact, was widely demonstrated that particular conditions could induce 
or inhibit aggregation processes[135][136]. 
The multiple methods used in parallel for the investigation, included UV-visible (UV-vis) ab-
sorption spectroscopy, which also gives information on the sample turbidity (Rayleigh Scatter-
ing), Fluorescence spectroscopy methods, and Circular Dichroism (CD), which gives infor-
mation on secondary structure changes. The sensitivity of fluorescence methods was exploited 
using multiple chromophores which allowed selectively the monitoring of specific properties 
of the samples. In particular, both intrinsic chromophores inherently present in proteins struc-
tures and extrinsic dyes, such as Thioflavin T (ThT) and 8-Anilino-1-naphthalenesulfonic acid 
(ANS), were used. The principle of all methods used are shortly described in the following 
paragraphs. 
2.5.1 UV-visible absorption Spectroscopy 
In this work, UV-vis Spectroscopy was mainly used to measure protein concentrations, thanks 
to the ability of proteins to absorb UV-vis light at 280 nm by the two aromatic residues, trypto-
phan (Trp) and tyrosine (Tyr), present in their amino acid sequence[137]. UV-vis spectra were 
recorded from 200 nm to 600 nm in order to verify also the presence of impurities. Furthermore, 
UV-vis spectra from 300 nm to 600 nm were recorded to measure the concentrations of fluo-
rescent dyes (as ThT and ANS). UV-vis spectroscopy was also used to monitor structural mod-
ifications of protein samples[133] and the growth of scattering intensity during kinetics exper-
iments. 
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2.5.2 Rayleigh Scattering 
A method to obtain qualitative information on the time evolution of aggregation processes, is 
based on the monitoring of the time evolution of Rayleigh peak during fluorescence measure-
ments. Scattering signal can be acquired simultaneously with fluorescence kinetics measure-
ments as it can be quantified monitoring the maximum of the elastic peak of excitation light 
during fluorescence measurements. This is because in dilute solutions, according to Rayleigh 
theory, if the particles size is smaller than the wavelength of incident light the scattered intensity 
from an N spherical non absorbing independent particles of V volume is given from: 
Is=ANV2 
Rayleigh Scattering represents then a good tool for following aggregation/polymerization ki-
netics especially at low protein concentration[138][139]. The time evolution of the scattering 
peak growth, in fact, may give information about time scale and lag phase of aggregation pro-
cesses and highlights the effect that different experimental conditions may have on 
them[15][140]. 
2.5.3 Intrinsic Fluorescence 
The Trp fluorescence emission changes depend on conformational rearrangements, the envi-
ronment around this residue, and/or changes in its solvent accessibility during aggregation pro-
cess[141]. In particular, Trp fluorescence intensity is known to be affected by the polarity of 
the environment, hydrogen bonding, and non-covalent interactions. During aggregation kinet-
ics, Trp residues may be exposed to the solvent, and as a consequence in most of the cases the 
fluorescence emission spectrum undergoes a red shift and decreases in fluorescence emission 
intensity[15][142]. Tyr residues have a lower quantum yield and minor sensitivity to the envi-
ronment and they are generally used as aggregation marker only when the protein in analysis 
lack of Trp. 
2.5.4 Thioflavin-T Fluorescence measurements 
ThT fluorescence was used to detect the growth of amyloid aggregates formation during the 
aggregation experiments, since its capacity to bind amyloid fibrils. Upon binding to amyloid 
fibrils ThT fluorescence intensity increases with a maximum at about 480 nm[143] and the 
emission band is linearly dependent on the amount of aggregates[144]. More detailed infor-
mation can also be extrapolated from data analysis, such as the presence of fibrils accessible 
during aggregation[20]. A large number of studies were performed to understand mechanisms 
behind ThT fluorescence specificity, and the more diffused model attributes the increase in ThT 
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fluorescence emission intensity to the rotational immobilization of the central C-C bond in ThT 
molecule upon binding to amyloid fibrils[145]. 
In this work, ThT fluorescence measurements were used to analyse the process of amyloid ag-
gregates formation by Atx3-Q14 and Atx3-Q54 variants, and also by Jos alone and in complex 
with K48-linked triUb chains. Importantly, when using ThT dye it is mandatory to do control 
measurements to assess that supramolecular assembly is not affected by the presence of the 
molecule. In fact, it was demonstrated that ThT may trigger amyloid aggregation[128], and also 
chemical changes of the dye may occur due to solution conditions and hinder reliable detec-
tion[146]. In order to verify that the use of ThT did not affect the aggregation process, meas-
urements were performed both in-situ and ex-situ ruling out a significant effect of the presence 
of the dye. 
2.5.5 8-Anilinonaphthalene-1-sulfonic acid fluorescence measurements 
ANS is a hydrophobic dye, widely used to obtain information on the conformational changes 
of hydrophobic regions of proteins, in their native states and during aggrega-
tion[147][148][149]. Moreover, detailed analysis of ANS fluorescence is a simple and efficient 
method to identify molten globule intermediate states of proteins. ANS, in fact, shows stronger 
affinity to molten globule-like intermediates than to native or unfolded states. This affinity de-
pends on the absence of rigid packing of hydrophobic clusters in these kind of states[150]. 
ANS is weakly fluorescent in aqueous environment but its fluorescence emission increases with 
a concurrent blue-shift in its emission maximum from ~510 to ~475 nm when located in a 
hydrophobic environment. Therefore, in the simpler cases, an increase in ANS fluorescence 
intensity accompanied by a blue-shift in the emission is observed upon oligomerization and 
fibrils formation[151]. 
2.5.6 Circular dichroism 
In order to evaluate if secondary structure changes occurred during aggregation experiments 
performed on the proteins under analysis, CD measurements were performed. CD spectroscopy 
is an absorption spectroscopy method, in the UV-vis range, which quantifies the differential 
absorption of circularly polarized light by chiral molecule. In this respect, CD technique can be 
applied to proteins structural studies[152]. In particular, CD spectra can be assigned to distinct 
structural features of proteins and give information on their secondary structure composition 
(%-helix-sheet, turns, etc.), and on conformational changes occurring during aggregation 
processes[153][154]. 
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Different structures show characteristic CD spectra (Fig. 2.10). In particular, α-helical proteins 
are characterised by two negative peaks centred at about 220 nm and 208 nm and a positive 
contribution at 193 nm[155]. Proteins with well-defined antiparallel β-pleated sheets present a 
large peak centred at 218 nm and positive bands at 195 nm, while disordered proteins have very 
low ellipticity above 210 nm and negative bands near 195 nm[156]. 
 
Figure 2.10: Typical CD spectra of proteins: in red CD spectrum of a protein with -helical secondary structure; 
in green with random coil, and in blue with -sheet. Figure adapted from [157]. 
2.5.7 Fluorescence Lifetime Imaging Microscopy 
Fluorescence lifetime imaging microscopy (FLIM) is a technique that allows mapping at pixel 
resolution of the fluorescence decay of fluorescent molecules, thus revealing details about the 
structure and dynamics of macromolecules together with spatial information at submicrometric 
resolution[158]. The analysis of fluorescence decay gives information on the lifetime of fluo-
rescent molecules (the average time in which the molecule remains in the excited state before 
returning to the ground state), which is specific of each fluorophore and highly dependent on 
the molecular environment. Importantly, fluorescence lifetime measurements do not depend on 
concentration of the molecule, potential presence of high scattering (which is common in ag-
gregated samples), and unlike intensity measurements it is not affected by instrumental details. 
A simple approach to analyse FLIM data is the phasor approach. The phasor approach gives 
information instantaneous and is not based on fitting, which would require the definition of a 
model or calculation, but it is a simple approach to analyse data and fluorescence imaging[159]. 
In phasor analysis, every pixel of the image is transformed to a point in the phasor plot: the 
coordinates g and s (sine and cosine transforms, respectively) of each point in the phasor plot 
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are calculated from the fluorescence-intensity decay in the corresponding pixel in the FLIM 
image[159]. In this way, every possible lifetime is mapped in the phasor plot. All possible single 
exponential lifetimes lie on the “universal circle,” defined as the semicircle going from point 
(0, 0) to point (1, 0), with radius 1/2. Point (1, 0) corresponds to τ = 0, and point (0, 0) to τ = ∞. 
As consequence, longer lifetimes are mapped near the origin of the axes and shorter lifetimes 
are mapped on the circumference toward the bottom right intersection with the x axis. In the 
phasor coordinates the single lifetime components add directly because the phasor follows the 
vector algebra. The clouds of points representing the fluorescence lifetime distribution over the 
two images are selected using a coloured circles in the phasor plot, so that the corresponding 
pixels are mapped back with selected colour to the image pixels[160]. 
In this work, FLIM was used to analyse the fluorescence signal resulting from UV-induced 
oxidation of three different proteins, Ub, Human Insulin and Aβ(1-40) peptide. Importantly, the 
use of FLIM experiments gave the possibility of highlight a substantial overlap between the 
signal due to the autofluorescence of tyrosine oxidation products, and the signal referred in 
literature as “Amyloid intrinsic fluorescence”. 
2.6 Experimental procedures 
2.6.1 Aggregation kinetic measurements of Atx3 variants, Jos and Ub 
The aggregation kinetics measurements of all samples were performed using similar methods.  
Ub aggregation process was induced incubating the sample at 60 °C under continuous excitation 
at 275 nm wavelength. The protein was placed in a 1 cm path quartz cuvette and spectra were 
recorded at 0.5 nm wavelength intervals, with excitation and emission bandwidth of 5 nm, scan-
speed of 100 nm/min, and integration time of 1 s. Ub was exposed at different exposition times 
for the duration of spectrum acquisition: every 6 minutes or every 30 minutes. Ub sample ag-
gregation was also induced at high temperature (60°C) or using stirring (500 rpm) under con-
tinuous irradiation. For each sample, emission spectra at 25°C, before and after kinetics, were 
measured to monitor significant variations of the emission band profile. Intrinsic fluorescence 
emission spectra for Ub analysis, were acquired in the range 270–700 nm with excitation at 275 
nm. Simultaneously, Rayleigh scattering was also measured as the maximum of the elastic 
peaks of excitation light at 275 nm. 
Atx3-Q14 and Atx3-Q54 aggregations were induced incubating the proteins at 50°C. In order 
to evaluate the role of external factors, such as pH and salt concentrations, kinetic measurements 
were performed at two different pH values (6.5 and 7.4), and in absence and in presence of salt 
(150mM NaCl). All samples were placed in a 1 cm path quartz cuvette, and spectra were 
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recorded at 0.5 nm wavelength intervals, with excitation and emission bandwidth of 2.5 and 5 
nm, respectively, scan-speed of 100 nm/min and integration time of 1 s. ThT fluorescence emis-
sion and ANS fluorescence emission were acquired to study the aggregates formation as a func-
tion of the incubation time of the sample at 50°C. ThT emission spectra were acquired in the 
range 435–700 nm with excitation at 440 nm, while for the ANS assay, the spectra were ac-
quired in the range 375–700 nm with excitation at 380 every 30 minutes.  
Kinetics measured of both free Jos and Jos/K48-linked triUb complex were performed incubat-
ing samples again at 50°C, but at a single condition of pH (6.5) and in absence of salt. The 
experimental parameters were the same used for Atx3 proteins. 
2.6.2 UV absorption measurements 
For all samples, absorption measurements were carried out before and after each aggregation 
experiment using a Jasco V-760 Spectrophotometer. Samples were placed in 1 cm path quartz 
cuvette and absorption spectra were acquired from 200 to 600 nm, using a scan speed of 100 
nm/ min, 1 nm bandwidth, data intervals of 0.5 nm and response of 0.96 s. 
2.6.3 Thioflavin T measurements 
ThT fluorescence was monitored using a Jasco FP-8500 spectrofluorimeter equipped with a 
Jasco ETC-815 peltier as temperature controller. Both, in-situ and ex-situ ThT measurements 
were performed. Regarding the ex-situ ThT measurements, the ThT dye was added to the sam-
ples immediately before the measurement, while to perform in-situ ThT measurements, the 
samples were incubated with ThT, and ThT fluorescence signal was detected in continuous.  
For in-situ ThT fluorescence assays of Atx3 variants and Jos, samples were incubated at 50°C 
without shaking with 25 µM ThT. All samples were placed in a 1 cm path quartz cuvette and 
spectra were recorded at 0.5 nm wavelength intervals, with excitation bandwidth of 2.5 nm and 
emission bandwidth of 5 nm, scan-speed of 100 nm/min and integration time of 1 s. During 
kinetic experiments, after thermal equilibration, ThT emission spectra of Atx3 variants and Jos 
samples, were obtained under excitation at 440 nm in the range 435–700 nm every 30 minutes. 
Simultaneously, Rayleigh scattering was also measured as the maximum of the elastic peaks of 
excitation light at 440 nm. For each sample, emission spectra at 25°C, before and after kinetics, 
were measured to monitor significant variations of the emission band profile. 
For ex-situ ThT measurements, Atx3-Q14 and Atx3-Q54 samples were incubated at 50°C in 
thermal bath for different time points: at 0 minutes; after 30 minutes; after 1 hour; after 2 hours; 
after 6 hours; after 12 hours; after 24 hours; and after48 hours. After thermal treatments, 25 µM 
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of ThT (as final concentration) were added to each sample, and ThT measurements were per-
formed at 25°C in quartz fluorescence cuvettes. The excitation wavelength was fixed at 440 nm 
and the emission intensity was monitored at 480 nm. 
2.6.4 ANS Fluorescence measurements 
ANS fluorescence emission spectra were recorded using a Jasco FP-8500 equipped with a Jasco 
ETC-815 Peltier thermostat. Samples were placed in a 1 cm path quartz cuvette, and all emis-
sion spectra were recorded at 0.5 nm wavelength intervals with excitation and emission band-
width of 2.5 nm and 5 nm, respectively, scan-speed of 100 nm/min, and integration time of 1s. 
Kinetic experiments, after thermal equilibration, were performed under excitation at 380 nm in 
the range 375–700 nm every 30 minutes. Excitation spectra were measured at 25°C before and 
after the kinetics to control possible variations of the excitation band profile. Simultaneously, 
Rayleigh scattering intensity was also measured as the maximum of the elastic peaks of excita-
tion light. 
2.6.5 CD measurements 
CD measurements in the Far-UV region for Ub samples were performed using a Jasco J-715 
spectropolarimeter equipped with a Jasco PCT 348WI temperature controller. Spectra were rec-
orded from 270 to 190 nm at 25°C, before and after thermal treatments, using a scan speed of 
50 nm/min, a 1 nm bandwidth, and a data pitch of 0.1 nm. Each spectrum is the result of the 
average of 5 accumulations. 
CD measurements of Atx3 variants, were performed at 50°C for about 20 hours, using a Jasco 
J-1500 spectropolarimeter equipped with a Jasco CTU-100 temperature controller. Each spec-
trum was recorded every 30 mins, from 270 to 190 nm, using a scan speed of 50 nm/min, a 2 
nm bandwidth, and a data pitch of 0.1 nm. Each spectrum is the result of the average of 2 
accumulations. 
2.6.6 FLIM measurements 
FLIM measurements were performed on Ub, Human Insulin and Aβ(1-40) peptide aggregates 
in the time domain using Leica TCS SP5 inverted microscope with a 63× oil objective (Leica 
Microsystems), equipped with PicoHarp 300 standalone TCSPC module (Picoquant). 256 × 
256 pixels images were acquired at a scanning frequency of 200 Hz under two-photon excita-
tion at 780 nm (Spectra-Physics Mai-Tai Ti:Sa ultra-fast laser). FLIM data were processed us-
ing the SimFCS software developed at the Laboratory of Fluorescence Dynamics, University 
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of California at Irvine. FLIM calibration was performed by measuring the known lifetime of 
the fluorescein that is a single exponential of 4.0 ns. 
2.7 In-cell studies 
To study Atx3 aggregation process in a physiological system, and if the interaction with polyUb 
chains can modulate it, an in-cell model was set up. For this purpose, cDNA for Atx3-Q14, 
Atx3-Q55, and linear M1-linked triUb were engineered and used to transient transfect human 
cell. Western blot analysis and immunofluorescence assay were performed in order to detect 
and localize the presence of the recombinant proteins in cell. In the following section, the ex-
perimental procedures used for the in-cell studies are described. 
2.7.1 Recombinant Atx3-Q14 and Atx3-Q55 for in-cell studies 
In order to study the Atx3 aggregation processes in human cells system, sequence of both Atx3 
isoforms, Atx3-Q14 and Atx3-Q55, were cloned into plasmids for mammalian expression. The 
Doxycycline-inducible vector pTet-ONE (Clonetech) was chosen in order to control and regu-
late the exogenous proteins expression during time. Human Embryonic Kidney 293 cells 
(HEK293) were used as host cells.  
In order to distinguish the endogenous from the exogenous proteins, all the DNAs sequences 
were engineered adding a Myc tag at N-terminal (Fig. 2.11). To do this, two PCR reactions 
were performed: the first to insert Myc tag, and the second one to generate sticky ends necessary 
for cloning the constructs into the pTet-ONE vector following a Gibson Assembly cloning strat-
egy[161]. This, also known as Seamless cloning, is a cloning method that permits to insert one 
or more DNA fragments into a vector without the use of restriction enzymes, thanks to com-
bined action of an exonuclease[107]. The method combines three enzymatic activities in a sin-
gle reaction: 5´exonuclease, 3´extension activity of a DNA polymerase, and DNA ligase activ-
ity. 
  
Figure 2.11: Domains organization of Atx3 constructs used for in-cell studies: a) Atx3-Q14 construct; b) Atx3-
Q55 construct. N-terminal Myc tag was added to both constructs to distinguish the endogenous from the exogenous 
proteins. 
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The strategies used to design the two couples of primers necessary to perform the two sequential 
PCR reactions mentioned above are reported in Fig. 2.12. Designed primers were purchased 
from IDT and are listed in Table 2.2. 
 
Figure 2.12: Primers design: a) alignment of primers used to insert Myc tag in the N-term region of Atx3 se-
quences. b) alignment of primers used to insert sticky ends useful to clone Atx3 sequence into pTet-ONE vector. 
In both a) and b), Myc sequence in green, and Atx3 sequence in cyan. 
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Primer name Primer sequence 
Fwd_Nter-Myc-
Atx3 
5’-gaacaaaaactcatctcagaagaggatctgatggagtccatcttccac-3’ 
Rev_Nter-Myc-
Atx3 
5’-gaacaaaaactcatctcagaagaggatctgatggagtccatcttccac-3’ 
Fwd_Nter-Myc-
Atx3_pTetONE 
5’-ccctcgtaaagaattcatggaacaaaaactcatctcagaa-3’ 
Rev_Nter-Myc-
Atx3_pTetONE 
5’- gcagagatctggatccttacttctttccttctgttttcaa-3’   
Table 2.2: Primers sequence to insert Myc tag to Atx3 sequence (green), and primers to clone Atx3 into in pTet-
ONE vector (red). 
The mixtures composition for the two PCR reactions are reported in Tables 2.3 and 2.4, while 
thermo-cycling conditions, same for the two PCRs, are reported in Table 2.5. 
 
Component Final Concentration 
milliQH2O  
Q5 Hot Start HF Master Mix 1X 
Fwd_Nter-Myc-Atx3 primer 0.5µM 
Rev_Nter-Myc-Atx3 primer 0.5µM 
Template DNA  1 ng 
Table 2.3: Mixture composition of the PCR reaction performed to insert the Myc tag in Atx3 sequence. As tem-
plates, Atx3-Q14 and Atx3-Q55 sequences from the pMAL bacterial expression vectors were used. 
 
Component Final Concentration 
milliQH2O  
Q5 Hot Start HF Master Mix 1X 
Fwd_Nter-Myc-Atx3_pTetONE primer 0.5µM 
Rev_Nter-Myc-Atx3_pTetONE primer 0.5µM 
Template DNA  1 ng 
Table 2.4: Mixture composition of the PCR reaction performed to generate sticky end to clone Atx3 sequences 
into pTet-ONE vector. As templates, Atx3-Q14 and Atx3-Q55 sequences generated for previous PCR (Table 2.2) 
were used. 
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Table 2.5: PCR thermal-cycling conditions 
After thermal-cycling reactions, the products from the first PCR step were incubated with DpNI 
enzyme for 30 minutes at 37°C, in order to remove the methylated DNA template, and then 
analysed by 0.8% agarose gel which confirmed the success of the amplification (Fig. 2.13). 
Confirmed PCR products were then purified and used as template for the second PCR step. 
Once confirmed the success also for the second PCR reaction, the resulting products were in-
cubated with empty pTet-ONE vector at 50°C for 30 minutes, following the manufacturing’s 
guidelines. 
 
Figure 2.13: Agarose gel analysis of Myc Atx3 PCR products: Lane 1: 1 kb DNA Ladder. Lane 2: PCR product 
for Myc-Atx3-Q14 amplification. Lane 3: PCR product for Myc-Atx3-Q55. The presence of the bands confirm 
that the expected amplification has taken place. 
Although the huge effort to produce pTet-ONE vectors for Atx3 expression, the system did not 
allow a high level of protein expression in HEK293 cells. Therefore, the two Atx3 constructs 
were sub-cloned into another vector for over-expression of proteins in human cells, pCI-Neo 
vector (Promega). This commercial vector allows over-expression in cells of recombinant pro-
teins continuously thanks to a cytomegalovirus (CMV) promoter. The strategy used to perform 
Step Temperature (°C) Time No. of Cycle 
Initial denaturation 98 30s 1 
   Denaturation 98 15s 
30    Annealing 65 15s 
   Extension 72 45s 
Final extension 72 2min 1 
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the sub-cloning into pCI-Neo vector was the multisite cloning, the most widely used method 
based on restriction enzymes[108]. In particular, Myc-tagged_Atx3-Q14 and Myc-
tagged_Atx3-Q55 were inserted into pCI-Neo between XhoI and NotI restriction sites (see vec-
tor map in Annex II). PCR reaction was performed in order to introduce XhoI and NotI re-
striction sites in both Atx3 DNA sequences. The primers design strategy is reported in in Fig. 
2.14. Designed primers were purchased from IDT and are listed in Table 2.6. PCR components 
and thermal cycling condition are reported in Tables 2.7 and 2.8, respectively. 
 
Figure 2.14: Primers design to introduce XhoI and NotI restriction sites in Myc Atx3-Q14 and Myc Atx3-Q55. 
Highlighted in green the sequence recognized by XhoI enzyme, and in cyan the sequence recognized by NotI 
enzyme. In both primers the sequence in red indicate the additional base pairs necessary to allow efficient cleavage. 
Primer name Primer sequence 
Fwd_Nter-
MycAtx3_XhoI 
5’-ccgctcgagatggaacaaaaactcatctcagaagag-3’ 
Rev_ Nter-
MycAtx3_NotI 
5’-gaaggattgcggccgcttacttctttccttctgttttc3’ 
Table 2.6: Primers sequences used to insert XhoI and NotI restriction sites in Atx3 sequences. Highlighted in 
green the sequence recognized by XhoI enzyme, and in cyan the sequence recognized by NotI enzyme. In red the 
additional base pairs necessary to allow efficient cleavage. 
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Component Final Concentration 
milliQH2O  
Q5 Hot Start HF Master Mix 1X 
Fwd_ NterMycAtx3_XhoI 0.5µM 
Rev_ NterMycAtx3_NotI 0.5µM 
Template DNA  1 ng 
Table 2.7: Mixture composition of the PCR reaction performed to insert restriction sites in Myc Atx3 sequences. 
As templates, Myc-tagged Atx3-Q14 and Myc-tagged Atx3-Q55 sequences from the pTet-ONE were used. 
Step Temperature (°C) Time No. of Cycle 
Initial denaturation 98 30s 1 
   Denaturation 98 10sec  
30 
 
   Annealing  65 30sec 
   Extension 72 2min 30sec 
Finale extention 72 2min 1 
Table 2.8: PCR thermal-cycling program performed to insert restriction sites in Myc Atx3 sequences. 
After thermal-cycling reactions, the PCR products were incubated with DpNI enzyme for 30 
minutes at 37°C, in order to remove the methylated DNA template, and then analysed by 0.8% 
agarose gel which confirmed the success of the amplification (Fig. 2.15). Empty pCI-Neo vec-
tor and both Atx3 PCR products were then digested with XhoI and NotI restriction enzymes to 
generate sticky ends. Insertion of the Atx3 sequences into the digested vector was performed 
thanks to the action of T4 DNA ligase enzyme, which allows the formation of phosphodiester 
bonds between the 3'-hydroxyl of one DNA terminus with the 5'-phosphoryl of another[108]. 
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Figure 2.15: Agarose gel analysis of Myc Atx3 PCR products with XhoI and NotI restriction sequences: Lane 1: 
1 kb DNA Ladder. Lane 2: Myc-tagged Atx3-Q14 in pTet-ONE plasmid used as template to generate Myc-tagged 
Atx3-Q14 with XhoI and NotI restriction sites. Lane 3: PCR product for Myc-tagged Atx3-Q14 amplification. 
Lane 4: Myc-tagged Atx3-Q55 in pTet-ONE plasmid used as template to generate Myc-tagged Atx3-Q55 with 
XhoI and NotI restriction sites. Lane 5: PCR product for Myc-tagged Atx3-Q55 amplification. The presence of 
the bands for the two PCR products confirm that the expected amplifications have taken place. 
2.7.2 Recombinant M1-linked triUb for in-cell studies 
To evaluate the interaction between Atx3 isoforms and polyUb chains in cell, a construct ex-
pressing linear M1-linked triUb was engineered and cloned into pCI-Neo vector between XhoI 
and NotI restriction sites (see vector map in Annex II). A HA tag was inserted at N-terminal 
region to detect the exogenous protein in cell (Fig. 2.16). DNA sequence was purchase by 
gBlocks Gene (IDT) already including the HA tag. 
 
Figure 2.16: Domain organization of linear M1-linked triUb used for in-cell studies. A HA N-terminal tag (red) 
was added to detect the over-expressed proteins. 
PCR reaction was performed in order to introduce XhoI and NotI restriction sites. The primers 
design strategy is reported in in Fig. 2.17. Designed primers were purchased from IDT and are 
listed in Table 2.9. PCR components are reported in Tables 2.10, while thermal cycling condi-
tions are the same of those reported in Table 2.8. 
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Figure 2.17: Primers design to introduce XhoI and NotI restriction sites in HA-M1-linked triUb construct. High-
lighted in green the sequence recognized by XhoI enzyme, and in cyan the sequence recognized by NotI enzyme. 
In red the additional bp. 
Primer name Primer sequence 
Fwd_3polyUb _XhoI 5’-ccgctcgagatgtacccatacgatgttccggattac-3’ 
Rev_ 3polyUb _NotI 5’-gaaggattgcggccgcctatccgcctcttagccg-3’ 
Table 2.9: Primers sequences used to insert XhoI and NotI restriction sites in HA M1-linked triUb sequence. 
Highlighted in green the sequence recognized by XhoI enzyme, and in cyan the sequence recognized by NotI 
enzyme. In red the additional base pairs necessary to allow efficient cleavage. 
Component Final Concentration 
milliQH2O  
Q5 Hot Start HF Master Mix 1X 
Fwd_3polyUb _XhoI 0.5µM 
Rev_ 3polyUb _NotI 0.5µM 
Template DNA HA- M1-linked triub gblock 1 ng 
Table2.10: Components and relative concentration for PCR reaction performed to insert restriction sites in HA-
tagged M1-linked triUb sequence. 
DpNI treatment, XhoI and NotI digestion, and ligation were then performed as already de-
scribed in the previous paragraph. In Fig. 2.18 the agarose gel of the PCR product is reported. 
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Figure 2.18: Agarose gel analysis of HA M1-linked triUb PCR product with XhoI and NotI restriction sequences: 
Lane 1: 1 kb DNA Ladder. Lane 2: PCR product for HA M1-linked triUb amplification. The presence of the band 
in Lane 2 confirms that the expected amplification has taken place. 
2.7.3 Transient transfection of Atx-3 variants and M1-linked triUb in HEK293 
In order to investigate on the interaction between Atx3 and polyUb chains in human cells, 
HEK293 cells were transient transfected using Myc-tagged Atx3-Q14, Myc-tagged Atx3-Q55 
and HA-tagged M1-linked triUb constructs. HEK293 cells are widely used in cell biology re-
search, because of their reliable growth and propensity for transfection. Cells were cultured in 
DMEM, high glucose, pyruvate (Gibco), supplemented with 10% heat-inactivated fetal bovine 
serum FCS (Thermo Fisher), 2 mM GlutaMAX (Gibco), 0.1% MEM no essential amino acids 
100X (Gibco). Cells were maintained in humidified 5% CO2/95% air, at 37°C until 24 hours 
then transfected. Transfection was performed by chemical transfection method, which is based 
on the use of cationic lipids able to interact with negatively charged DNAs. The resulting li-
pids/DNA complexes are able to pass through the cell membrane, probably by endocytosis and 
phagocytosis process, and the exogenous DNA is translated into the protein of interest[162]. In 
this work, Lipofectamine 3000 Reagent (Invitrogen) was used as chemical transfecting agent 
following the manufacturing instructions. 2.5 μg of each plasmid was incubated with 5 μl of 
Lipofectamine, and the complex was then added to HEK293 cells at 70-90% confluence in 6-
wells plates. To evaluate the effect of triUb on Atx3 expression and aggregation, co-transfection 
of the two relative plasmids was performed. Transfected cells were then maintained in humid-
ified 5% CO2/95% air, at 37°C for 48 h. Cells transfected with green fluorescent protein (GFP) 
construct were used as control of transfection. 
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2.7.4 Detection of Ataxin-3 variants and triUb in human cell 
To verify the level expression of the proteins of interest, and to test the efficiency of transfection 
in cells, western blot analysis was performed[163]. Cell lysates containing 15 μg of total pro-
teins were denatured for 5 min at 100°C in Laemmli sample buffer, and subjected to SDS-
PAGE analysis, using 12.5% polyacrylamide gels (Life Technologies). The proteins contained 
in the lysates were separated by size in the gel, and were then transferred from the gel to a 
Polyvinylidene fluoride (PVDF) membrane (Thermo Fisher) in 1x transfer buffer (0.25M Tris, 
1.92M glycine, 20% methanol).  Western blotting was carried out using the mini Trans-Blot 
electrophoretic transfer system (Bio-Rad) for one hour at 100 V. In order to verify the proteins 
transfer from the gel to the membrane, staining for 5 minutes with Ponceau Red (Sigma-Al-
drich) was performed. The membranes were blocked for 1 hour in 1x casein blocking buffer 
(SIGMA), in order to saturate all non-specific binding sites reducing the background. Mem-
branes were immune-stained over night at 4°C with specific primary antibodies. The primary 
antibodies used were: rabbit polyclonal anti-Atx3 1H9 clone antibodies (1:500, dilution), rabbit 
polyclonal anti-Myc antibodies (1:1000, dilution), mouse anti-HA antibodies (1:1000, dilution) 
and anti-Tom20 antibodies (1:5000, dilution).  The primary antibodies are usually coupled with 
signal-inducing secondary antibodies. For these experiments were used as secondary antibod-
ies, Alexa Fluor 680 goat anti-mouse IgG antibody (1:20000, dilution, red) and Alexa Fluor 
488 goat anti-rabbit IgG secondary antibodies (1:20000, dilution, green). Secondary antibodies 
conjugated with fluorophores were detected by fluorescence detection system Odissey CLx (LI-
COR). 
2.7.5 Localization of Ataxin-3 variants and triUb in human cell 
Immunofluorescence assays were performed to detect and localize over-expressed exogenous 
proteins in transfected HEK293 cell line. Generally, immunofluorescence assay is used on bi-
ological samples to detect proteins in cellular contexts using specific antibodies, giving infor-
mation on localization of detected proteins in cellular compartments.  
Immunofluorescence assays can be direct and indirect. In the first case, a primary antibody 
conjugated with a fluorophore is used both to capture the protein of interest and for detection.  
In the second case, a primary antibody is used to capture the protein of interest, and it is then 
recognized by a secondary antibody conjugated with a fluorophore for detection by fluorescent 
microscope analysis[164]. In this experimental work, indirect fluorescence assays were per-
formed. After 48 hours from transfection, HEK293 cells were fixed in 4% paraformaldehyde 
(PFA) pH 7.4, permeabilizated with 1% Triton-X 100. For blocking step, 3% fetal bovine serum 
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(FCS) in PBS was used. Cells were then immune-stained with the following primary antibodies: 
rabbit polyclonal anti-Atx3 1H9 clone antibodies (1:100 dilution) to detect both endogenous 
and exogenous Atx3 proteins; rabbit polyclonal anti-Myc antibodies (1:8000 dilution) was used 
to detect Atx3 exogenous proteins; mouse anti-HA (1:1000; dilution) was used to detect exog-
enous triUb. Alexa Fluor 568 goat anti-mouse IgG antibody (red), 1:1000, dilution, and Alexa 
Fluor 488 goat anti-rabbit IgG secondary antibodies (green), 1:1000, dilution, were used as 
secondary antibodies. Nuclei were stained with 4′,6-diamidino-2-phenylindole dihydrochloride 
(DAPI). The cells were visualized using a DM5000B microscope (Leica Microsystems, Wetz-
lar, Germany). 
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3 Results 
In this section, experimental results obtained in this work will be described. The aim of the 
project “Understanding the relationship between normal function and aberrant aggregation: 
the case of ataxin-3” (PON industrial PhD program) is to evaluate, in the case of Atx3, if and 
how the molecular interaction between specific polyUb chains and Atx3 could affect aberrant 
Atx3 aggregation, and thus pathogenic mechanisms involved in SCA3. As previously reported, 
Atx3 is a ubiquitin hydrolase, which physiologically binds and cleave specifically, K48-linked 
polyUb chains [80][90][165]. An ideal experimental approach to reach the project goals would 
involve the study of the conformational properties and aggregation pathways of individual K48-
linked polyUb chains, and then the analyse of these when in interaction with Atx3. Unfortu-
nately, the low quantities of polyUb chains that can be obtained by enzymatic reaction prepa-
ration (as explained in chapter 2) discouraged to proceed in the separate analysis of the confor-
mational stability of these molecules. As an alternative route, mUb as a standard model was 
used as it is the main subunit of polyUb. This allowed the development of a suitable experi-
mental platform and, simultaneously, the analysis of the conformational properties this protein. 
In section 3.1, the experimental analysis of the thermally induced aggregation processes of 
mUb, and the analysis of its conformational and structural changes under destabilizing condi-
tions, are reported. Importantly, in this part of the study modifications induced by UV light on 
Ub were pointed out. In particular, structural changes and oxidation of Tyrosine residues were 
found to be induced by illumination from the Xenon lamp of the spectrofluorometer during 
kinetic measurements in aggregation conditions. Target residues were highlighted together with 
changes in protein structure at molecular level and the appearance of a new fluorescence peak 
in the visible region characteristic of the oxidation process. Importantly, this peak can be put in 
relation with the literature regarding the so called “amyloid intrinsic fluorescence signature” 
which exists in the same range. 
In section 3.2, results of experimental studies on aggregation processes of the non-pathological 
variant Atx3-Q14 and the expanded variant Atx3-Q54 are presented. Different physical-chem-
ical conditions allowed to highlight the role of electrostatic and hydrophobic interactions in the 
evolution of the process. The model proteins were produced introducing a suitable mutation 
(C14A) that inactivates the protein catalytic site, and as a consequence reduce both the catalytic 
activity against polyUb chains and the Atx3 self-cleavage activity. Presented data unambigu-
ously show that both proteins, in the selected experimental conditions, follow the same aggre-
gation pathway, independently on polyQ tract length. In the framework of recent literature, this 
result can be interpreted taking into account the experimental conditions and clearly highlights 
Results 
46 
the dominant role of Jos domain and of auto-cleavage mechanisms in pathological aggregation. 
In-cell experiments in HEK293 cells were also performed, aimed at analysing cellular localiza-
tion of the selected Atx3 variants and their toxicity when overexpressed. Evidences are pre-
sented highlighting that Atx3-Q14 and the expanded variant Atx3-Q55 interact in analogous 
way with triUb molecules in cellular environment, and that in the presence of triUb self-cleav-
age events are reduced. 
In-vitro and in-cell studies encouraged to proceed, in-vitro, with the experimental characteriza-
tion of the interaction between Jos domain and specific triUb chains, which were suitably syn-
thetized by enzymatic reaction. Results indicate that, in line with the hypothesis of the project, 
native-native interaction with natural binders, in conditions where heterogeneous mechanisms 
are suppressed, reduce abnormal aggregation and pave the way to further studies on inhibitors 
derived from natural binders of relevant proteins involved in polyQ pathologies. 
3.1 In-vitro analysis of thermal and UV-illumination effects on Ubiquitin 
Ub is a small protein, evolutionarily conserved in all eukaryotes, involved in several cellular 
pathways. The principal biological role of Ub is the involvement in the ubiquitin proteasome 
system, that regulates proteins degradation in cells. In fact, proteins targeted to degradation are 
ubiquitinated, thanks to covalent attachment of Ub molecule or polyUb chains before degrada-
tion, and this post translational modification permits their recognition by the degradation pro-
teasome system[166]. 
A multiplexed experimental approach based on spectroscopic techniques, as UV-Visible ab-
sorption and, fluorescence spectroscopy, light scattering and circular dichroism, was used to 
analyse Ub conformational properties under stress conditions as high temperature, stirring and 
UV- Illumination. 
The interest on UV-exposure effect depends on the implication that this exposition could have 
on proteins structure and functions. Indeed, proteins, for their UV absorption characteristics 
and their abundance in cells, are primary targets of UV-mediated cellular damages, and the 
effects of UV-induced oxidation on structure and function and its implications in human pa-
thologies has been widely investigated[167]. 
Importantly, experimental results have shown that UV-light exposure induces irreversible oxi-
dation processes in Ub structure. In particular, changes attributable to the formation of oxidation 
products of tyrosine were observed, and in particular the formation of di-tyrosine and DOPA. 
Structural modifications induced by UV-light exposure were found to modify thermal stability 
of the protein inducing significant variations in its aggregation pathway. 
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These results have a specific interest for the present thesis study as they deal with the further 
analysis of interactions between Atx3 and polyUb chains on aggregation process. Even more 
importantly, they are of a great interest from a general point as target residues and changes in 
protein structure at molecular level have been highlighted under UV-stress. Indeed, reported 
results increase the number of information on the relation between oxidation processes, molec-
ular mechanisms in aggregation, and on the methods to monitor these events also in relation to 
supramolecular assembly of proteins. Ub was selected as a model system but presented results 
indicating that analogous results can be obtained also in other system with no tryptophan resi-
dues in protein sequence. This gives a general valence to presented findings. Moreover, in view 
of the fact that considerable evidences link UV‐induced oxidative stress to skin cancer, and that 
ubiquitination process was shown to have a key role in regulating tumor‐promoting or tumor 
suppressing pathways, the present study may also assume specific relevance. 
Importantly, the obtained results can also be put in relation with the literature regarding the so 
called “amyloid intrinsic auto fluorescence signature”, a largely debated topic in the last 
years[168][169]. The signal due to tyrosine oxidation exists in the same range with analogous 
feature, so that it may represent a significant hindrance in the specific detection of amyloid 
intrinsic fluorescence, or it is also possible to infer that the electronic levels that become avail-
able when tyrosine is oxidized may be at least one component of the dim blue signal which 
make fibrils observable in the visible range with standard laser scanning confocal or two photon 
microscopes. The findings challenge the simple attribution of “amyloid intrinsic auto fluores-
cence” and point the finger at the need for attention to details of sample preparation, and to 
control experiments especially with the development of extremely sensitive instrumentation 
and automated methods. 
Figure 3.1a reports the time evolution of emission fluorescence spectra of 0.5 mg/ml Ub incu-
bated at 60°C, for 24 hours. Spectra were acquired every 20 minutes under continuous excita-
tion at 275 nm. The illumination due to the excitation light was kept constant for all the duration 
of the measurement. 
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Figure 3.1: a) Time evolution of fluorescence emission spectra of 0.5 mg/ml Ub in 20mM sodium phosphate 
buffer, pH 6.5, incubated at 60°C for 24h. Fluorescence spectra were acquired every 20 minutes with continuous 
excitation at λexc=275 nm. The arrows indicate the changes of the signals as a function of time. b) Fluorescence 
emission spectra measured at room temperature of 0.5 mg/ml Ub in 20mM sodium phosphate buffer, pH 6.5, 
before (blue line, blue axis) and after (red line, red axis) incubation at 60°C for 24h under continuous UV exposure. 
Figure modified from [133]. 
A decrease in fluorescence emission intensity around 350 nm and an increase at 450 nm was 
observed, as indicated by arrows (Fig. 3.1a). Figure 3.1b reports Ub fluorescence emission 
spectra measured at room temperature before and after thermal treatment (60°C). Significant 
spectral modifications are observed. In the time-evolution experiments, before irradiation, Ub 
showed a maximum peak around 350 nm, typical of native Ub. Under UV irradiation, the peak 
centred at 350 nm decrease, while a corresponding increase in the blue region of the emission 
spectrum, with a maximum around 470 nm, was observed. The observed changes were irre-
versible and did not occur if the sample was not subjected to continuous UV irradiation (data 
not shown). 
Measurements reported in Fig. 3.1a revealed a progressive reduction in fluorescence intensity 
signal linked to tyrosine while, in parallel the growth of a new peak centred at 470 nm is ob-
served. Data did not show the presence of an isosbestic point, indicating that the observed 
changes are consequence of multiple phenomena causing the modification of optical properties 
of the sample. 
The main peak at lower wavelength (350nm) is attributable to the emission of the unique tyro-
sine residue of the protein[124][170][171]; the Tyr residue in position 59 is, indeed, the sole 
responsible of intrinsic fluorescence of Ub[172]. 
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Although less sensitive to changes in the environment than tryptophan residues[125][173], Tyr 
residues have often been used to monitor conformational properties and aggregation processes 
in proteins. Tyr has significantly lower quantum yield than Trp residue and it is used as an 
intrinsic fluorescent probe only for proteins without Trp residues in their se-
quence[170][174][173]. In the case of Ub, time resolved fluorescence study in the ps range have 
suggested that changes in Tyr quantum yield, varying pH, are caused by the interaction with 
other residues in the surroundings and by the formation of tyrosine-carboxylate hydrogen-
bonded complex and tyrosinate[124][175]. Data in the literature suggest that the new band in 
the blue region, centred at 470 nm can be assigned to oxidation products of tyrosine, such as 
dityrosine and tyrosinate, as reported in [176][177][178]. In particular, the observed spectral 
changes can be correlated with the formation of tyrosine oxidation products, involving cycliza-
tion and decarboxylation[132][173]. These changes can be  related with the oxidation of tyro-
sine residues resulting in the formation of different products, with optical activity[179][174], 
such as dityrosine [180][175][171], Dihydroxyphenylalanine (DOPA) and some hy-
droxycinnamoyls[178]. Di-tyrosine formed by UV irradiation are found to show similar spec-
tral changes as reported in Fig. 3.1. 
 
Figure3.2: Ub absorption spectra before and after thermal treatment at 60°C under UV exposure. a) Absorption 
spectra of 0.5 mg/ml Ub sample before (blue line) and after (red line) incubation at 60°C for 24h, under continuous 
UV-exposure at UV-light at excitation wavelength at λexc=275 nm. b) Differential Absorption spectrum due to the 
continuous UV exposure. Blue lines at 280, 300 and 350 nm are guides for eyes. Figure modified from[133]. 
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Figure 3.2a shows Ub absorption spectra before and after thermal incubation at 60°C for 24 
hours, under continuous UV exposure in the same conditions as the one in Fig 3.1. In figure 
3.2b the difference spectrum between treated and untreated sample is also reported to better 
highlight the occurrence of two new absorption peaks. 
After incubation of Ub at 60°C, an increase of turbidity is clearly observed, attributable to an 
increased scattering of the solution due to aggregation[177]. Most interestingly, in the absorp-
tion spectra reported in Fig. 3.1b, UV exposure caused the growth of two new significant com-
ponents in the absorption spectrum, one centred at 300 nm and one, more evident in raw data, 
centred at 350 nm. These observations are in line with the formation of tyrosine oxidation prod-
ucts. In particular, similar modifications in the absorption spectrum are considered, as a marker 
of di-tyrosine formation and of protein oxidation, responsible for several diseases, which have 
been associated to aging processes or exposure to UV-light[15][181]. 
In order to evaluate if the oxidation of Tyr residue is due only by UV irradiation, or depends on 
other factors that could influence the process, the sample was irradiated under different expo-
sition conditions, such as protein concentration, temperature and agitation of the sample. 
 
Figure 3.3: Fluorescence emission intensity as a function of time measured at 350 nm a) and at 470 nm b) for 0.5 
mg/ml Ub in 20mM sodium phosphate, pH 6.5, incubated at 60°C for 22 hours; Ub was exposed to UV light 
(λexc=275 nm), continues UV-exposure (dark red circles), for 3 minutes (time of spectrum measurement) every 6 
minutes (red circles), and for 2 minutes every 30 minutes (pink circles). Figure modified from[133] . 
Figure 3.3 reports the kinetics of fluorescence spectral changes for three identical Ub samples, 
incubated in the same conditions as before, but using three different protocols of irradiation 
during the fluorescence measurements: continuous irradiation (dark red circles), irradiation 
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only for the duration of spectrum acquisition every 6 minutes (red circles), and every 30 minutes 
(pink circles). 
Interestingly, exposing Ub for different times of UV radiation, significant changes are observed 
in the evolution of fluorescence peak signal changes. The samples exposed to UV light for 
longer times (continuous exposure) show a decrease of fluorescence intensity which reaches a 
plateau in about 15 hours. Sample with intermediate exposure (every 3 minutes and every 6 
minutes) reaches a plateau in 20 hours, while for the sample with the shortest exposure the 
plateau is not observed even after 36 hours. These results suggest that the effect corresponding 
to the tyrosine residue oxidation, is caused by UV irradiation. 
In order to highlights other possible factors, Ub samples at three different protein concentrations 
(0.5,0.7 and 1.8 mg/ml) were incubated at 60°C, under continuous exposure to UV-light for 24 
hours. 
 
Figure 3.4: a) Rayleigh scattering intensity measured at 275 nm as function of time, for three different protein 
concentrations. b) and c) Normalized fluorescence emission intensity as a function of time measured respectively 
at 350 and at 470 nm, at different protein concentrations. Figure modified from[133]. 
Fig. 3.4 shows the time evolution of Rayleigh scattering (a), and fluorescence intensity meas-
ured at 350 nm (b) and at 470 nm (c), respectively. The results in Fig. 3.4a showed that after a 
short lag-phase lasting about 5 hours, the Rayleigh scattering intensity started to increase as 
function of time. The observed growth of Rayleigh scattering showed that Ub at 60°C forms 
aggregates and this aggregation process depended on protein concentration. Although Ub is 
highly stable[182], presented data indicate that in the presented experimental conditions the 
protein is able to form aggregates, and that the fluorescence spectral changes, related with Tyr 
oxidation, are not affected by aggregation extent. Moreover, while Rayleigh scattering, here 
used as a measure of aggregation in solution, started to increase only after few hours of incu-
bation, fluorescence spectral changes were observed since the very beginning of the kinetics 
(Fig. 3.4b and c), strongly suggesting that the two processes are independent. 
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With the aim of evaluating  if modification in Ub fluorescence spectra changes may occur also 
in conditions where aggregation is not observed, we performed analogous experiments at 25°C. 
Figure 3.5 shows a comparison between data obtained at high temperature 60°C, and at 25°C. 
Rayleigh scattering measurements clearly indicate that no aggregation occurs at 25°C (Fig. 
3.5a), while spectral modifications could still be observed (Fig. 3.5b and c). 
 
Figure3. 5: Rayleigh scattering intensity at 275 nm as function of time. a) Fluorescence emission intensity as a 
function of time, measured at 350 nm b) at 470 nm c) for Ub at a concentration of 1.8 mg/ml, incubated at 60°C 
and at 25°C. In panel c), dashed grey lines are guide to the eye, to highlight the different rates in the increase of 
the fluorescence intensity measured at 470 nm. Figure modified from[133]. 
Significant changes in fluorescence peak profile are observed, whose rate depends on temper-
ature. The variations of fluorescence emission intensity at 470 nm are reported in Fig. 3.5c, 
where dashed grey lines are used as eye guide to highlight the different slopes of the two kinet-
ics and to elicit the change of slope occurring in kinetics at 60°C, which is not observed at 25°C 
within the experimental observation time. Measures in Fig. 3.5 highlight that the effect of tem-
perature and UV-light cannot be easily disentangled, but the variation of signal attributed to 
formation of tyrosine oxidation products occurs both in conditions were aggregation occurs 
(60°C) and in conditions were aggregation is not observed (25°C). Probably, high temperature 
facilitates the oxidative processes induced in tyrosine by UV-irradiation. 
Furthermore, Ub aggregation can be induced also at low temperature by subjecting the sample 
to stirring (see Fig. 3.6a). The comparison between the fluorescence data observed with or with-
out stirring (Fig. 3.6b and c) again confirms that the aggregation has no effect on the kinetics 
of the spectral changes occurring in tyrosine fluorescence. For sample under stirring, the mon-
otonic decrease of fluorescence intensity at 350 nm was observed from the initial stage during 
the lag phase of aggregation. Fluorescent spectra modifications overlapped both in stirring and 
quiescent conditions. 
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Figure 3.6: Rayleigh scattering intensity at 275 nm a) and Fluorescence emission intensity measured at 350 nm 
b), and at 470 nm c) as a function of time. 1.8 mg/ml Ub samples in 20mM sodium phosphate, pH 6.5, for 48h 
were incubated at 25°C, stirring at 500 rpm (red circles) and in quiescent conditions (blue circles).Figure modified 
from[133]. 
In sum, all reported data indicate that UV exposure induces modifications in Ub UV–Visible 
absorption and in its fluorescence signal that can be ascribed to the formation of tyrosine oxi-
dation products. This process is facilitated by high temperature but occurs both in aggregation 
conditions and in conditions were massive supramolecular association is not observed. 
Results reported above single out modifications induced by UV light in Ub, by UV illumination 
from the xenon lamp of a spectrofluorometer during kinetic measurements in aggregation con-
ditions. Spectral modifications and, in particular, the growth of a fluorescence peak in the blue 
region is attributable to tyrosine oxidation and in particular to dityrosine and DOPA. 
Ub aggregates formed at high temperature in the presented conditions were found to be not 
positive to ThT, a worldwide used fluorescent molecule used to selectively stain amyloid ag-
gregates[143][183]. The absence of ThT fluorescence excludes the amyloid nature of the ag-
gregates formed by Ub, as also confirmed by CD spectra and FTIR spectra reported in Fig. 3.7 
a) and b), respectively, in which transitions to -sheet structure was not observed. The above 
observations rule out any possible contribution in all the above reported measurements of the 
so called “Amyloid autofluorescence” which lies in the same spectral range[184]. 
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Figure 3.7: a) Circular Dichroism spectra of 0.5 mg/ml Ub sample in 20mM sodium phosphate buffer, pH 6.5, 
before (green line) and after (purple line) incubation at 60°C for 24h. b) FTIR spectra in the amide I’ region (1575 
cm-1 – 1710 cm-1) of 1.8 mg/ml Ub sample in 20mM sodium phosphate buffer, pH 6.5, before (blue squares) and 
after (magenta circles) incubation at 60°C for 72h, under continuous excitation at 275 nm. Spectra are normalized 
to their maximum. Figure modified from[133]. 
In Figure 3.8a the contour plot of fluorescence emission intensity in the range 350-700 nm as a 
function of excitation light in the range 280- 450 nm is reported for Ub sample after incubation 
at 60°C for 72 hours under continuous UV exposure. In Fig. 3.8b emission profiles for selected 
excitation wavelengths are shown, and in Fig. 3.8c differential absorption spectrum is reported 
as a reference.  These data show the complex nature of the newly formed species, indeed, the 
observed fluorescence signal shows at least two components attributable to two energetic levels 
which correspond to different species. According to the literature, these changes can be at-
tributed to the formation of tyrosine oxidation products such as tyrosinate (emission maximum 
at 430 nm) and di-tyrosine (maximum peak at 410 nm), which can be formed under our exper-
imental conditions[177][178][185]. 
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Figure 3.8:  3D fluorescence spectra/contour maps for Ub (1.8 mg/ml), acquired at room temperature after incu-
bation at 60°C for 72 hours, under continuous excitation at 275 nm. a) Horizontal lines indicate the excitation 
wavelengths relative to representative emission spectra, which are reported in panel b). c) Differential adsorption 
spectrum between treated and native sample, showing the variations in absorption profile due to the treatment. 
Figure modified from [133]. 
Importantly, this measurement highlights that the blue fluorescence emission peak is observable 
using excitation wavelengths other than the one typically attributed to tyrosines (<290 nm). In 
particular, the new fluorescent peak is excited also at higher wavelengths, corresponding to the 
new absorption peaks in the absorption spectrum reported in Fig. 3.2. Interestingly, we note 
that the fluorescence signal in the blue range (i.e. above ~450 nm) can be detected and isolated 
also at excitation wavelengths above 350 nm, i.e. in the same range used in the literature to 
excite “amyloid autofluorescence peak”. 
In order to gain further information on this fluorescence signal, fluorescence lifetime measure-
ments were also performed. Fluorescence Lifetime Imaging (FLIM) was used to this aim. Fig-
ure 3.9 reports FLIM measurements on 1.8 mg/ml Ub after incubation at 60°C for 72 hours, i.e. 
in the conditions of data in Fig. 3.8. In this sample the largest spectral changes induced by UV-
irradiation are detectable. Representative intensity images of two regions of the sample are 
shown: one where a uniform distribution of fluorescence is measured linked to the presence of 
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species with size under instrumental spatial resolution (a), and one where, together with diffuse 
fluorescence signal, a large micrometric size aggregate was present, characterized by higher 
intensity (b). Images were acquired under two photon excitations at 780 nm, i.e. at excitation 
wavelength corresponding to larger intensity of the fluorescence band centred at 430 nm. 
 
Figure 3.9: Fluorescence intensity images (60µm x 60µm) of 1.8 mg/ml Ub after incubation at 60°C for 72 h, 
under continuous UV-exposure. Panel a) shows a region of the sample with species under resolution and panel b) 
an area with large aggregates. c) and d) Selection maps of Ub, corresponding to the fluorescence images a) and 
b), respectively. Pixel are coloured depending on their lifetime values. e) Phasor plot, showing the distribution of 
Ub lifetimes after treatment. Red and green cursors select two different lifetime distributions. The size of the 
images is 60 µm a) and b). Excitation wavelength was λexc= 780nm; Detection range: 430-700 nm. Figure from 
[133]. 
FLIM measurements were analysed by means of the so called phasor approach[159][186]. The 
corresponding maps and phasor plot are reported in Fig. 3.7c and d and in Fig. 3.7e, respec-
tively. The output of the phasor analysis gives a graphical view of all the measured fluorescence 
decays at each pixel in the images. In the phasor plot, each point represents the fluorescence 
lifetime at each image pixel. Single exponential lifetimes are represented as points laying on 
the so called “universal circle”. Longer lifetimes are found near the origin of the axes, and 
shorter lifetimes are found on the circumference toward the bottom right intersection with the 
x axis. The position of the phasor in the universal circle, after system calibration (see paragraph 
2.5.7 for details) determines the lifetime values. The fluorescence lifetime distribution over the 
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two images is represented by the clouds of points that are selected using a coloured circle and 
the corresponding pixels are mapped back with the selected colour to the image.  
These measurements were put in comparison with analogous measurements performed on In-
sulin and Amyloid β samples, which are worldwide used models for studies on amyloid struc-
tures formation. In particular, the experiments were performed on Human Insulin and Aβ(1–
40) peptide, since both proteins are able to form amyloid fibrils, and do not present tryptophan 
residues in their sequence. Furthermore, it was observed that oxidative stress negatively affects 
neurodegenerative diseases such as Alzheimer's and Parkinson's disease[187], and also is in-
volved in the induction of insulin resistance in Type II diabetes[188], being a link between these 
pathologies[189][190]. 
In order to compare the spectral changes observed for Ub, both Insulin and Aβ(1–40) peptide 
were exposed to UV light excitation at 275 nm. Figure 3.10 reports fluorescence emission spec-
tra and representative 1024x1024 confocal fluorescence microscopy images of aggregated sam-
ples stained with ThT. Human Insulin aggregates were obtained by incubating the protein at 
60°C in 20mM sodium phosphate buffer at pH 6.5 with stirring at 500 rpm for 24 hours. Sample 
was kept under continuous UV- illumination at 275 nm during the aggregation process. 
Panel a) of Fig. 3.10 reports fluorescence emission spectra at room temperature acquired in the 
range 280-650nm using exc=275 nm before (blue line) and after UV treatment at 60°C (pink 
line). Panel b) of the same figure reports differential spectra with respect to the first thermalized 
one of Human Insulin intrinsic fluorescence during the described treatment at 60°C. Repre-
sentative confocal fluorescence microscopy images reported in panels c-f) clearly show that 
aggregates are positive to ThT thus confirming the expected amyloid nature of these structures. 
Importantly, spectral modifications observed in panel a) and b) do not occur if aggregates are 
produced in the dark and. The spectral modifications observed for this sample are analogous to 
those observed for Ub samples after exposition to UV light. 
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Figure 3.10: 0.2 mg/ml Human Insulin in 20mM sodium phosphate buffer, pH 6.5 was incubated at 60°C with 
500 rpm stirring for 24 hours under continuous excitation at 275 nm. a) Fluorescence emission spectra acquired in 
the range 280- 650nm using exc=275 nm measured at room temperature before (blue line) and after treatment 
(pink line). b) Differential spectra with respect to the first thermalized one of Insulin intrinsic fluorescence during 
the described treatment at 60°C. The arrows indicate the changes of the signals as a function of time. c)-f) 
1024x1024 Representative confocal fluorescence microscopy images of Insulin fibrillar aggregates stained with 
ThT. Fluorescence signal is excited using a continuous laser line at λexc =458 nm and acquired in the range 470-
650 nm. Figure from[133]. 
Analogous measurements were performed on Aβ(1–40) peptide and results are reported in Fig. 
3.11. Aggregates were obtained by incubating 0.2 μM Aβ(1–40) in 20 mM sodium phosphate 
buffer, pH 6.5 at 37°C with stirring at 500 rpm for 24 hours. Sample was kept under continuous 
UV light illumination at 275 nm. 
Panel a) of Fig. 3.11 reports fluorescence emission spectra at room temperature acquired in the 
range 280- 650nm using exc=275 nm before (cyan line) and after treatment (pink line). In panel 
b) differential spectra with respect to the first thermalized one of A intrinsic fluores-
cence during the described treatment at 37°C. Panels c-e) reports 1024x1024 representative 
confocal fluorescence microscopy images of the aggregated sample. Also in this case, ThT flu-
orescence indicates that, in the presented conditions, Aβ(1–40) peptide forms amyloid aggre-
gates. In line with measurements on Human Insulin, spectral modifications do not occur if 
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aggregates are produced in the dark.  These results confirm that both proteins that are able to 
form amyloid aggregates, when exposed to UV light show the similar spectral changes observed 
for Ub. 
 
Figure 3.11: 0.2 μM Aβ(1–40) in 20 mM Na phosphate buffer, pH 6.5, was incubated at 37 degrees stirring at 500 
rpm for 24 hours under continuous excitation at 275 nm. a) Fluorescence emission spectra acquired in the range 
280- 650nm using exc=275 nm measured at room temperature before (cyan line) and after treatment (pink line). 
b) Differential spectra with respect to the first thermalized one of A intrinsic fluorescence during the described 
treatment at 37°C. The arrows indicate the changes of the signals as a function of time. c)-e) 1024x1024 Repre-
sentative confocal fluorescence microscopy images of A fibrillar aggregates stained with ThT. Fluorescence sig-
nal is excited using a continuous laser line at λexc =458 nm and acquired in the range 470-650 nm. Figure from[133]. 
Human Insulin and Aβ (1-40) peptide, after incubation at 60°C and 37 °C, respectively, expe-
rienced the same decrease of fluorescence emission around 310 nm and the increase around 450 
nm under continuous UV-exposure (λexc=275 nm). The observed absorption and fluorescence 
spectra modifications, which can be attributed to the formation of tyrosine oxidation products 
occur in similar way, both in amyloid and non-amyloid forming samples. 
FLIM measures confirmed the presence of newly formed fluorescent species whit analogous 
properties as the ones reported for Ub. Importantly, an overlap of both steady state and time 
resolved fluorescence measurements is observed.  This is shown in Fig. 3.12 where comparison 
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between FLIM measurements on Ub, Human Insulin and Aβ (1-40) peptide samples are re-
ported. In the selection maps (Fig. 3.12 d-f) red pixels corresponding to same lifetime in phasor 
plot (Fig.3.12 g) are picked. Interestingly, all the aggregates reveal an analogous lifetime dis-
tribution, strongly suggesting the same origin for the blue autofluorescence signal observed in 
all samples. 
 
Figure 3.12: Fluorescence intensity images of Ub; a) Human Insulin b) and Aβ(1-40) c); d), e) and f): Selection 
maps corresponding to the same regions. g) Phasor plot representing the distribution of lifetimes in every pixel in 
the presented images. Red cursor is used to select pixels with the same lifetime. All proteins were incubated under 
continuous irradiation at λexc=275 nm. Excitation wavelength was λexc: 780 nm; Detection range: 430-700 nm. 
Figure from[133]. 
The three proteins analysed have as common structural property the lack of tryptophan residues 
in their sequence, that could quench tyrosine fluorescence protecting tyrosine residues against 
UV-induced oxidation[191]. As a control, analogous experiments were performed on Bovine 
Serum albumin (BSA) in sodium phosphate buffer, pH 6.5 at 60°C and no significant spectral 
modifications were observed (data not shown). All samples after prolonged UV exposure, under 
two photon excitations at 780 nm, show an intrinsic blue fluorescence in the region 430–700 nm 
with the same lifetime distribution. In particular, the identical intrinsic fluorescence was re-
vealed as well as in Ub amorphous aggregates, that do not bind ThT, and Insulin and Aβ fibrils 
which are selectively stained by ThT. In vitro dityrosine formation was previously also ob-
served in α-synuclein samples[181], and in Aβ (1–42) fibrils grown under oxidative stress con-
ditions were observed[192]. Furthermore, a UV-light induced visible fluorescence in the blue 
range was also observed in A deposits from human brain[193]. 
As a further control, measurements on polyalanine amyloid fibrils, which do not contain tyro-
sine, were performed. Aggregates were induced by incubating polyalanine at 60°C for 24h in 
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20 mM glycine pH 11, under continuous UV- illumination at 275 nm. Confocal fluorescence 
microscopy images of polyalanine fibrillar aggregates stained with ThT clearly indicated the 
presence of large ThT-positive aggregates (Fig. 3.13 a-f). Furthermore, the steady state fluores-
cence measurements measured at λexc =275 nm and λexc =350 nm indicated that no fluorescence 
signal exists in these conditions (Fig. 3.13 g and h). 
 
Figure 3.13: Polyalanine 8mg/ml was incubated at 60°C for 24h in buffer glycine 20 mM pH 11 giving rise to 
amyloid fibrils. Before imaging samples were diluted 1:5 in phosphate buffer pH 5 (to avoid ThT hydroxylation) 
and then stained with ThT. a), b) d) and e) 1024x1024 Representative confocal fluorescence microscopy images 
of polyalanine fibrillar aggregates stained with ThT. c) Superimposition of 35 μm z-stack; f) Superimposition of 
15 μm z-stack of c. In all images, fluorescence signal is excited using a continuous laser line at λexc =458 nm and 
acquired in the range 470-650 nm. g), h) Steady state fluorescence measurements of Polyalanine fibrils imaged in 
a)-e) λexc =275 nm and 350 nm. Figure from[133]. 
Results described in this section unambiguously show that UV-light induces structural modifi-
cation in Ub molecule ascribable to Tyr oxidation. These results highlight how simple experi-
mental measurements may induce unsought significant changes in the structure of proteins. 
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Importantly, the presented measurements also show that, under specific experimental condi-
tions, Ub was also able to form aggregates with non-amyloid nature. 
To the aim of the present work, it is also important to underline that the observed modifications 
occur during standard measurements conditions, and this has been taken into account in plan-
ning subsequent experiments. The propensity shown by mUb to UV oxidation is likely to be 
persistent in polyUb chains and this has to be taken in account both in the production and in the 
analysis steps. Suitable control measurements based on fluorescence when then set up to ex-
clude samples with oxidative modifications. 
Data also presented represent a caveat for studies on the interaction between polyUb chains and 
Atx3 protein. 
3.2 In-vitro Aggregation study of Ataxin-3: the case of Atx3-Q14 and Atx3-
Q54 
SCA3 belongs to a group of nine polyQ diseases caused by expansion of the polyQ tract of 
Atx3 protein above a specific repeat length threshold [60][194]. The pathological hallmark of 
SCA3 is represented by the formation of aggregates in cellular inclusions. These intranuclear 
aggregates consist of Atx3 proteins aggregates and also proteins involved in proteasome path-
way system[65]. 
As discussed in Chapter 1, although the aggregation processes of Atx3 aggregation was widely 
investigated [95][195][196][197], the complex pathway of Atx3 self-assembly is not fully elu-
cidated yet. In this work, the study of Atx3 aggregation mechanism is aimed at investigating on 
the conditions that could modulate the Atx3 aggregation process, and on the role of specific 
regions of the protein involved in the interaction with its physiological partners, polyUb chains, 
and how this interaction could modulate the aggregation process. 
Atx3 aggregation process was then analysed in order to understand the underlying molecular 
mechanisms in the pathology. Two Atx3 variants with different polyQ tract length, namely 
Atx3-Q14 and Atx3-Q54, were selected because, according to the literature, should present 
different pathological implications. The two Atx3 variants have been expressed in prokaryotic 
cells, which resulted a suitable system for obtaining folded and active pure proteins to be used 
in aggregation studies. In particular, the isoforms containing 3UIMs in the C-terminal region 
were chosen, because these isoforms are those mainly expressed in brain tissue[198][199]. 
Moreover, both Atx3-Q14 and Atx3-Q54 were produced with the point mutation C14A, that 
inactivates the catalytic site of Atx3. This allows the reduction of Atx3 autocleavage propensity 
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as the production of free polyQ fragments may interfere with the aggregation processes analysis 
inducing heterogeneous nucleation mechanisms[99]. 
Here, Atx3 protein aggregation mechanisms have been analysed by different techniques such 
as ThT, ANS fluorescence and CD spectroscopy. These methods aimed at analysing Atx3 ag-
gregation pathway in conditions that may highlight dominant interactions and structural 
changes involved in supramolecular assembly. This is aimed at assessing a well-defined starting 
point to evaluate the effect of polyUb chains interaction on Atx3 aggregation. 
Surprisingly, the obtained results did not show nucleation-dependent aggregation pathways, 
and also no significant differences in the aggregation processes of the two Atx3 variants were 
observed. Probably, in the tested experimental conditions, the use of an expanded Atx3 variant 
with a border line pathological expansion of polyQ (Q54), and in the absence of self-cleavage, 
did not allow the appreciation of the contribution of the polyQ tract in the aggregation process. 
This in turn allowed to analyse common processes that mainly interest the N-terminal region, 
Jos domain, which obviously is the same in the two proteins. 
The aggregation kinetics of Atx3 variants were studied using ThT fluorescence. This being one 
of the most frequently used methods to monitor amyloid formation. As detailed in the method 
section, the growth of ThT fluorescence intensity takes in account for the growth of amyloid 
structures in solutions[143][145]. In the initial stage of these experiments, both in-situ and ex-
situ measurements were performed in order to assess that the dye presence was not affecting 
aggregation process. Subsequently only in-situ measurements were performed, since the two 
methods gave identical results, and the characteristic times of supramolecular assembly (about 
two hours) are short enough to exclude artefacts due to ThT hydroxylation[146]. 
The aggregation processes of Atx3-Q14 and Atx3-Q54 were evaluated incubating the proteins 
at 50°C. Figg. 3.14 and 3.15 report result of ex-situ experiments of both Atx3-Q14 and Atx3-
Q54, performed in 20mM sodium phosphate buffer with 1mM TCEP, pH 6.5. Samples were 
freshly prepared, and then incubated at 50°C in a thermal bath up to 72 hours.  
Figure 3.14 reports absorption spectra (a), ThT fluorescence emission spectra (b), and far-UV 
CD spectra (c) of Atx3-Q14 after incubation at 50°C for different incubation time points. The 
same measurements were performed for Atx3-Q54 and relative results are reported in Fig. 3.15. 
For both Atx3 proteins, all spectra were acquired at 25°C after suitable incubation times: after 
30 minutes; after 1 hour; after 2 hours; after 6 hours; after 8 hours; after 24 hours; 48 hours; 
and after 72 hours. All measurements are referred to the one on sample before incubation, in-
dicated as 0 minutes. 
As shown in Figg. 3.14a and 3.15a, absorption spectra for both samples appear to be modified. 
This modification is ascribable to the increase of turbidity signal which takes into account for 
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the growth of aggregates species in solution. Notably, the observed changes in absorption spec-
tra were closely similar for both Atx3 samples. 
These results show that, for both Atx3 proteins, ThT fluorescence intensity and scattering pro-
gressively grow as a function of time reaching an apparently constant value after about 24 hours. 
These observations suggest that, in the presented conditions, both samples undergo aggregation 
forming amyloid like species with no appreciable differences. 
In line with fluorescence results, far-UV CD spectra show similar secondary structures changes 
for the two Atx3 variants, consisting of a decrease of signal around 220 nm corresponding to 
an increase in sheet content in the proteins (Figg. 3.14c and 3.15c). 
 
Figure 3.14:Ex-situ measurements of 18M of Atx3-Q14  in 20mm Na phosphate with 1mM TCEP, pH6.5, after 
incubation at 50°C samples is withdrawn and brought back at 25°C after different times: 30 minutes; 1 hour; 2 
hours; 6 hours; 8 hours; 24 hours;48 hours and 72 hours. As a refence the measurements on freshy prepared sample 
is also reported (t0 min). a) UV visible absorption spectra of the samples after different incubation times at 50°C 
in the range 225-450 nm b) ThT fluorescence emission spectra recorded at 25°C 26M ThT, excitation wavelength 
was exc=440nm detection range 435-600 nm. c) normalized far-UV CD spectra, recorded at 25°C in the range 
260-190 nm, using a scan speed of 50 nm/min, a 1 nm bandwidth. Each spectrum is the result of the average of 5 
accumulations. 
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Figure 3.15: Ex-situ measurements of 18M of Atx3- Q54  in 20mm Na phosphate with 1mM TCEP, pH6.5, after 
incubation at 50°C samples is withdrawn and brought back at 25°C after different times: 30 minutes; 1 hour; 2 
hours; 6 hours; 8 hours; 24 hours;48 hours and 72 hours. As a refence the measurements on freshy prepared sample 
is also reported (t0 min). a) UV visible absorption spectra of the samples after different incubation times at 50°C 
in the range 225-450 nm b) ThT fluorescence emission spectra recorded at 25°C using 26M ThT, excitation 
wavelength was exc=440nm and detection range 435-600 nm. c) normalized far-UV CD spectra recorded at 25°C 
in the range 260-190 nm, using a scan speed of 50 nm/min, a 1 nm bandwidth. Each spectrum is the result of the 
average of 5 accumulations. 
This pivotal screening allowed to highlight that in the selected conditions aggregation sudden 
occurs and that ThT positive aggregates are formed. The ThT fluorescence and CD measure-
ments were consistent and showed that both Atx3-Q14 and Atx3-Q54 present similar trend. 
Moreover, the analysis showed high reproducibility of measurements, and although it was ob-
served the formation of amyloid like aggregates, no lag phases or nucleation-dependent aggre-
gation pathways were observed both, in-situ and ex-situ ThT measurements. These suggest that 
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probably Atx3 aggregation follow other mechanism involved in amyloid aggregates for-
mation[15][200]. 
Figure 3.16 reports the comparison of in-situ ThT fluorescence emission spectra at 480 nm as 
function of time of both, Atx3-Q14 and Atx3-Q54, incubated at 50°C for 3 hours. The ThT 
emission fluorescence increased for both proteins, reaching the plateau phase in about 2 hours. 
These results confirmed the ex-situ ThT measurements, showing that Atx3-Q14 and Atx3-Q54, 
in 20mM sodium phosphate with 1mM TCEP pH 6.5, were able to form ThT positive aggre-
gates and that the supramolecular assembly kinetics overlap. 
 
Figure 3.16: Comparison of in- situ ThT fluorescence emission intensity measured at 480 nm as a function of time 
of 18M of Atx3-Q14 (cyan dots) and 18M of Atx3-Q54 (pink dots)  in 20mM Na phosphate with 1mM TCEP, 
pH6.5, incubated at 50°C for 3 hours, with 26M ThT. It was used exc=440nm, detection range 435-600nm. 
Interestingly, the changes of ThT fluorescence intensity, reaching the plateau after 2 hours, 
correlate in the range time with the changes observed in ThT ex-situ assay reported in Figg. 
3.14b and 3.15b. 
These results differ from the larger part of results previously reported in literature on Atx3. 
Indeed, in the present study both proteins undergo aggregation with superimposable kinetics 
and no significant differences were observed between Atx3-Q14 and the expanded Atx3-Q54. 
Nucleated mechanisms were observed by Ellisdon and co-workers in ex-situ ThT measure-
ments, but, notably, their analysis was performed at 37°C using a higher proteins concentration 
in a much complex buffer with respect the conditions used in this thesis work, In particular, 
they used 30 M proteins samples, in tris-buffered saline (TBS) pH 7.4 containing 10% (v/v) 
 Results 
67 
glycerol, phenylmethylsulfonyl fluoride (2 mM), EDTA (5 mM), and -mercaptoethanol 
(15mM)[94][95]. Another work, performed by Chow and co-workers, again showed that ex-
panded Atx3-Q50 forms fibrils faster than non-expanded forms Atx3-Q15 and Atx3-Q28. 
Again, it is notable that also in this case temperature and buffer conditions were different with 
respect those used in the present thesis work. They performed ex-situ ThT assay using similar 
protein concentration than the one used here, but incubated samples at 37°C in PBS buffer[197]. 
More in-situ aggregation studies were performed by Scarff and co-workers on Atx3-Q14 and 
Atx3-Q78 isoforms, incubating at 37 °C for about 48 hours without shaking, in 250 mM am-
monium bicarbonate, 1 mM DTT, pH 8.1[201]. Common feature of these studies being lower 
temperature and higher pH than the one used in the presented experiments. Although, expansion 
of the polyQ tract has been demonstrated to accelerate Atx3 aggregation, polyQ expansion is 
also reported not to modify Atx3 stability or folding/unfolding process[197], this suggesting 
that in present conditions aggregation is modulated by the folded part of the molecule. In line 
with this hypothesis, several works demonstrated that at least the first phases of aggregation is 
triggered by Jos domain, while further following phases involve the polyQ 
tract[95][98][102][202][203]. 
A possible significant difference between the experimental protocol here performed and the 
ones that highlighted nucleation mechanisms in Atx3, may consist in the use of an optimized 
purification protocol designed to produce high purity and fresh protein for each experiment.  
Furthermore, samples here analysed contain the point mutation C14A, that inactivates the cat-
alytic site, and incubation was performed at higher temperature than physiological. These dif-
ferences in the experimental procedures, may have allow to highlight non nucleated mechanism 
common to both variants. 
In order to highlight that no difference between the two variants exists at secondary structure 
level, far-UV CD spectra were acquired at 25°C before and after incubation at 50°C for 20 
hours (Fig. 3.17). As can be seen, no significant secondary structure differences between the 
two Atx3 variants are found comparing in pair spectra before and after thermal treatment. 
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Figure 3.17: Comparison of far-UV CD spectra of 18M of Atx3-Q14  before (dark blue line) and after (light 
blue line) incubation at 50°C for 20 hours and 18M of Atx3-Q54  before (dark red line) and after (orange line) 
incubation at 50°C for 20 hours, in 20mM Na phosphate with 1mM TCEP, pH6.5. Far-UV CD spectra were rec-
orded at 25°C in the range 260-190 nm, using a scan speed of 50 nm/min, a 1 nm bandwidth. Each spectrum is the 
result of the average of 5 accumulations. 
The obtained data reflect that both Atx3-Q14 sample and Atx3-Q54 sample, in the tested con-
ditions, undergo to profound changes in the structure, but these changes appear not to be de-
pendent on polyQ length. Notably, the observed changes show similar modification to the no 
expanded Atx3-Q15 and Atx3 variants without polyQ tract (QHQ) observed by Ellisdon and 
colleagues[94]. Results reported till now have highlighted the monotonic growth of amyloid 
aggregates, this growth is paralleled by changes at secondary structure level leading to the for-
mation of intermolecular -sheets. In literature the growth of amyloid fibrils via a non-nucle-
ated assembly mechanism involving the formation of intermolecular β-sheets was previously 
observed[204][205]. Many observations underline how the subtle balance between electrostatic 
and hydrophobic interactions affects the formation and stability of the organized hydrogen bond 
network constituting fibrils spine[206][207][208]. 
In order to evaluate how hydrophobic interactions are involved in the observed aggregation 
processes, the properties of the ANS dye were exploited. This was aimed both at elucidating 
the conformational changes in the solvent exposure of hydrophobic regions during aggregation 
and at exploring hydrophobic sites that may have different roles in the interaction with polyUb. 
Indeed, ANS fluorescence measurements are widely used to study the conformational changes 
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during aggregation process highlighting the role of hydrophobic regions of proteins if present. 
As discussed in Chapter 2, ANS is an extrinsic dye frequently used for protein folding and 
aggregation studies, that presents a fluorescent signal strongly dependent on the polarity of its 
environment[151]. Generally, a blue shift of fluorescence emission maxima and the increase of 
fluorescence intensity is observed when ANS binds the hydrophobic patches of proteins. Figure 
3.18 shows ANS fluorescence spectra of freshly prepared Atx3-Q14 and Atx3-Q54, recorded 
in 20mM sodium phosphate buffer with 1mM TCEP, pH 6.5, before incubation at 50°C. 
 
Figure 3.18: ANS fluorescence spectra of 18M Atx3-Q14 (blue line) and 18M Atx3-Q54 (red line) with 20 M 
ANS in 20mM Na phosphate buffer with 1mM TCEP, pH 6.5. The spectra were recorded at 25°C. excitation 
wavelength was exc =380nm; detection range: 400-600 nm. 
As it is evident, Atx3-Q54 samples are characterised by higher fluorescence intensity signal, 
indicating that the expanded Atx3 variant has larger affinity to ANS with respect to Atx3-Q14. 
This possibly is because hydrophobic part of Atx3 are more exposed in presence of longer 
polyQ tract. 
Figure 3.19 reports the analysis of ANS fluorescence measurements of both Atx3-Q14 and 
Atx3-Q54 in 20mM sodium phosphate buffer with 1mM TCEP, pH6.5, incubated at 50°C for 
6 hours. Steady state fluorescence emission of ANS was acquired as a function of time every 6 
minutes in the range 375-700 nm using excitation wavelength exc =380nm. Panel a) reports the 
time evolution of ANS fluorescence intensity measured as the area of emission peak between 
394 nm e 692 nm. Panel b) reports the average peak position. 
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Figure 3.19: a) ANS fluorescence intensity measured as the area of emission peak between 394nm and 692nm as 
function of time b) Average position of the ANS fluorescence peak measured as a function of time, of 18M Atx3-
Q14 (green dots) and 18 M Atx3-Q54 (pink dots) with 20 M ANS, in 20mM Na phosphate buffer with 1mM 
TCEP, pH 6.5 incubated at 50°C for 6 hours. Excitation wavelength was exc =380nm; detection range: 375-700 
nm. 
Data show that ANS intensity increases for both Atx3-Q14 and Atx3-Q54 for about 2 hours, 
indicating the formation of new hydrophobic sites in the same time range observed in previous 
analysis using ThT. ANS intensity shows a similar trend for both samples, increasing to a max-
imum and then slightly decreasing. In Atx3-Q14 sample the maximum value is reached in a 
shorter time. The peak position also indicates the formation of new hydrophobic binding sites 
for ANS and suggest a slower process for Atx3-Q54 variant. Small differences are highlighted 
which are not detected by ThT fluorescence measurements. These effects can be considered as 
negligible for their effect in supramolecular assembly, but need further investigations for ex-
ample on samples with larger polyQ expansion. 
In order to better establish the conditions for further analysis, and to understand the differences 
between our observations and nucleation-dependent pathway reported in literature, aggregation 
analysis of Atx3-Q14 and Atx3-Q54 was performed using different conditions, and in particular 
changing electrostatic conditions which strongly influence the amyloid formation.  
It is known that protein aggregation is influenced by local environment, as solution pH, ionic 
strength and protein concentration[26][209][210]. Salt have large effect on the structure and 
properties of proteins, by varying the ionic strength is possible to modify the protein native state 
properties, conformation, and inter- and intra-molecular interactions. 
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Low concentration of salt is reported to stabilize protein structures through non-specific elec-
trostatic interactions, while high concentration salt may hinder their stability and solubil-
ity[211]. This effect is caused by favourable interactions between salt ions and charges on pro-
tein surfaces. Atx3 in the analysed conditions is positively charged as its isoelectric point is 
4.67, as consequence the addition of salt has the effect of shielding the exposed ionic charges. 
This allows to modify electrostatics interactions to investigate possibly different effect related 
to different in the polyQ tract length. Moreover, this allows getting closer to experimental con-
ditions of reference studies in the literature, many of which were performed in buffers contain-
ing NaCl at physiological concentrations (about 150mM) [94][196][197][212]. 
Figure 3.20 reports ThT fluorescence emission intensities measured at 480nm as a function of 
time of both Atx3-Q14 and Atx3-Q54 in 20mM sodium phosphate buffer, with 1mM TCEP, 
pH6.5, in solution with 150mM NaCl during thermal incubation at 50°C. Measures in the ab-
sence of NaCl in the same experimental conditions are reported for comparison. 
As observed in Fig. 3.20, for both Atx3-Q14 and Atx3-Q54, in the presence of salt a monotonic 
growth of ThT intensity is observed to a lower plateau value with respect to one reached by the 
same samples in the absence of salt. Moreover, it is evident that the plateau is reached with a 
faster rate. In fact, the plateau was reached in less than 30 minutes. However, no significant 
differences were observed comparing Atx3-Q14 and Atx3-Q54 in absence of salt and in pres-
ence of 150mM NaCl. 
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Figure 3.20: Time evolution of ThT fluorescence intensity measured at 480 nm of 18 M Atx3-Q14 and 18 M 
AtxQ54 with 26 M ThT, in 20mM Na phosphate buffer 1mM TCEP, pH6.5, incubated at 50°C for 3 hours, Atx3-
Q14 without salt (light green dots) and with 150mM NaCl(cyan dots); Atx3-Q54 without salt (dark green triangle) 
and with 150mM NaCl (blue triangles).  
The observed reduction of ThT intensity cannot be directly attributed to a lower number of 
amyloid structures in solution, because of the exquisite sensitivity of fluorescence signals meas-
ured in the presence and in the absence of salt. This difference could be attributable to different 
environments experienced by the dye, due to difference in the ThT binding sites which may 
lead to different dye quantum yield, and/or to differences in the refraction index of the sample 
which may lead to alteration in measured signal. 
In order to verify that also in these conditions it is possible to observe a growth of inter-molec-
ular -sheet Far-UV CD spectra recorded at 220 nm for both Atx3 variants while incubating 
samples at 50°C for 3 hours in absence and in presence of 150mM NaCl. Figure 3.21 reports 
the Far-UV CD as a function of time and highlights that variations in CD signals at 220nm 
present analogous behavior for the two samples and both in the absence and presence of salt, 
being the last ones slightly faster. 
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Figure 3.21: Time evolution of Far-UV CD spectra measured at 220 nm of 18 M Atx3-Q14 and 18 M Atx3-
Q54 incubated at 50°C for 3 hours, in 20mM sodium phosphate, 1mM TCEP, pH 6.5 in absence and in presence 
of 150mM NaCl. Atx3-Q54 without salt (dark pink tringles) and with 150mM NaCl (light pink triangles) and 
Atx3-Q14 without salt (dark cyan circles) and Atx3-Q14 with 150mM NaCl (cyan circles). 
Notwithstanding the low signal to noise, these data confirm that the aggregation process is 
slightly accelerated when in solution is present salt, probably caused by minor electrostatic 
repulsion. This effect does not seem to depend on the length of polyQ because in both Atx3-
Q14 and Atx3-Q54 proteins the same behaviour was observed, again the structural changes are 
possibly ascribable to Jos domain. 
These data suggest that the electrostatic interactions, modulate the supramolecular assembly, 
however since the pI of Atx3-Q14 and Atx3-Q54 is 4.67 this effect may be poorly evident. For 
a quick exploration was performed a higher pH moving away from the pI. Indeed, changing pH 
conditions, it is possible to perturb the net charge of a protein and its conformational properties 
and to modulate electrostatic interactions during the aggregation pathway during aggrega-
tion[213]. Figure 3.22 shows ThT fluorescence emission at 480nm as a function of time of 
Atx3-Q14 and Atx3-Q54 while incubating samples at 50°C for 10 hours, at pH 7.4. In the same 
figure, results obtained at pH 7.4 are compared with the one obtained at pH 6.5, previously 
reported in Fig.3.16. 
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Figure 3.22: Time evolution of ThT fluorescence emission at 480 nm of 18 M Atx3-Q14 and 18 M Atx3-Q54 
in 20mM Na phosphate with 1mM TCEP, incubated at 50°C for 10 hours with 26 M ThT. Atx3-Q14 at pH 6.5 
(green dots) and at pH 7.4(green triangles) and Atx3-Q54 at pH 6.5 (red dots) and at pH 7.4(red triangles). 
As expected, at pH 7.4, away from the pI of Atx3, the aggregation process is slowed down and 
an increase in the formation of ThT positive aggregates was observed. The data are in line with 
the results reported by Chow and co-workers that analysed three Atx3 variant (Atx3-Q15, Atx3-
Q28 and Atx3-Q50) aggregation using a wide range of pH (1.9-8) by means of several spectro-
scopic methods, as ThT, ANS and Far-UV CD measurements. Indeed, Chow and co-workers 
observed that polyQ tract did not affect the aggregation process of all the three Atx3 vari-
ants[197]. 
At pH 7.4 a reduction of aggregation rate is observed for both samples, the supramolecular 
assembly show a different shape allowing the observation of a concave profile in the initial 
stage. Importantly, also in these conditions no differences are observed between the two vari-
ants confirming consistent results over a wide range of experimental conditions. Ionic strength 
and pH conditions were explored and, as expected, they affected aggregation following general 
law regulating amyloid like growth at low concentrations[210]. 
Importantly, this highlighted that Atx3-Q14 and Atx3-Q54 do not show significative difference 
in their aggregation behaviour and this suggests that in the tested conditions a possible contri-
bution of polyQ length on the aggregation process was not observed. Further investigation using 
an Atx3 variant with larger expansion in polyQ tract are certainly needed, and for this reason 
an Atx3 variant with more than 70Q has been already produced in the industrial partner labs. 
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3.3 In-cell co-expression of Ataxin-3 and tri-Ubiquitin chains 
In this section results obtained in cellular environment are reported, aimed at analysing the 
behaviour of analysed Atx3 variants and possible interaction with triUb chains. 
Hallmark of SCA3 pathology is the presence of nuclear inclusions in the cell of patients, that 
not only contain Atx3 aggregated but also polyubiquitinated proteins[69][215]. Several works 
investigated on expression of Atx3 variants in cell system and in mouse model[216][217]. In-
terestingly, it has been observed that Atx3 with longer polyQ tract, was more prone to form 
nuclear aggregates in cells, while the non-expanded Atx3 protein could also form smaller ag-
gregates that remain in cytoplasm[218]. 
In order to study also the Atx3 variants behaviour in cell model, Atx3-Q14 and Atx3-Q55 were 
over-expressed in Human Embryonic Kidney (HEK293) cells to evaluate differences on cell 
cytotoxicity, and on the ability to form cell aggregates determined by the expansion of the 
polyQ tract. Moreover, to also test in cell the possible interaction between Atx3 and polyUb 
chains, a linear triUb DNA construct was generated. Western blot analysis and immunofluores-
cence assay were used to verify the expression of the exogenous proteins in cell system and to 
monitor the localization and the possible interaction between Atx3 and triUb in cellular envi-
ronment. 
Atx3-Q14 and Atx3-Q55 proteins were engineered to generate suitable DNAs constructs that 
could be expressed in cells. In order to recognize exogenous Atx3-Q14 and Atx3-Q55 from 
endogenous proteins, both DNAs constructs were modified by adding a Myc tag in their N-
terminal region, and then they were cloned into vector for mammalian expression, as described 
in Chapter 2. The expression of the exogenous proteins was verified transfecting human cell 
line HEK293. As a control of the transfection method it was used a DNA construct expressing 
a fluorescent green protein (GFP), easily detected by fluorescence microscopy analysis. After 
48 hours of transfection, the total protein extracts from transfected cells were evaluated by 
western blot analysis. This was possible thanks to the Myc tag that was recognized by specific 
antibodies, permitting to distinguish the exogenous proteins from endogenous proteins ex-
pressed at basal levels in cells. An antibody against Atx3 protein was also used, able to recog-
nize both Atx3-Q14 and Atx3-Q55 by binding the region between Jos domain and polyQ tract. 
As first experimental approach, Atx3 constructs were generated for an inducible expression 
system in human cells, using the inducible vector pTet-ONE. This vector permits to control 
high level expression of gene of interest, thanks to a control of a promoter, regulated by the 
presence of Doxycycline (Dox) in the cultured medium. This system was suitable to regulate 
the over-expression of exogenous proteins at different times. This approach was unsuccessful 
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because did not allow a good level of expression of exogenous proteins in cell. pCI-Neo no-
inducible vector was then used, which is able to over-express proteins continuously in human 
cells. Figure 3.23 reports the western blot analysis of cell lysates from HEK293 cells transfected 
with Atx3 variants cloned in pTet-ONE vector, and those obtained using the pCI-Neo vector. 
After 48 hours transfection, cells were lysate and the total proteins extract was analysed by 
western blot. For western blot analysis an antibody against Atx3 was used. An antibody against 
Tom 20 protein was used as a control of analysis. 
 
Figure 3.23: Western blot analysis, using Anti-Atx3 clone 1H9 antibody, of cell lysate from HEK293 cells trans-
fected with  Atx3-Q14 (lane 1)and Atx3-Q55(lane 3) in pTet-ONE vector, and with  Atx3-Q14 (lane 2)and Atx3-
Q55(lane 4) in pCI-Neo vector; Anti-Atx3 GFP plasmid was used as a control of transfection(lane 5); Anti-Tom20 
antibody were used as a control. 
As shown in Fig. 3.23, comparing the two expression strategies, the use of the pCI-Neo vector 
clearly increases the level expression of exogenous proteins. Considering the good results ob-
tained using pCI-Neo vector, the vector was used also to generate a construct for expression of 
triUb protein in human cells. Although Atx3 shows high affinity of binding for K48-linked 
polyUb chains, it was not possible generate in cell recombinat K48-linked triUb. A linear M1-
linked triUb was then generated with HA tag to distinguish exogenous construct from proteins 
in cells, and in order to visualize simultaneously Atx3 constructs and linear M1-linked triUb. 
In order to investigate on the interaction between Atx3 isoforms and M1-linked triUb chains in 
cell model, HEK293 were co-transfected with a combination of Myc-tagged Atx3-Q14 and 
linear HA-tagged M1-linked triUb, or with a combination of Myc-tagged Atx3-Q55 and linear 
HA-tagged_M1-linked triUb, as described in chapter 2. 
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Figure 3.24: a) Western Blot analysis using Anti-Myc antibody, of cell lysate form HEK293 cells transfected with 
both Atx3-Q14 (lane 1)and Atx3-Q55 (lane 2)constructs alone, and western blot analysis of cell lysate form 
HEK293 cells co-transfected with both Atx3-Q14 (lane 3)and Atx3-Q55 (lane 4) with HA-M1-linked triUb; b) 
Western Blot analysis using Anti-HA antibody of cell lysate form HEK293 cells co-transfected with Atx3-Q14 
(lane 1)and Atx3-Q55(lane 3) with HA-M1-linked triUb and HA-M1-linked triUb  alone(lane 5). GFP plasmid 
was used as a control of transfection; Anti-Tom20 antibody were used as a control of the method. 
Figure 3.24 shows the western blot analysis of cell lysates from HEK293 cells transfected for 
48 hours with: i. Myc-tagged Atx3-Q14 alone; ii. Myc-tagged Atx3-Q14 co-expressed with 
linear HA-tagged M1-linked triUb; iii. Myc-tagged Atx3-Q55 alone; iv. Myc-tagged Atx3-Q55 
co-expressed with linear HA-tagged M1-linked triUb. In panel a) detection of both Atx3-Q14 
and Atx3-Q55 constructs was revealed by using anti-Myc antibody while in panel b) anti-HA 
antibody was used in order to recognize exogenous triUb. As in western blot analysis reported 
in Fig. 3.23 antibody against Tom 20 protein was used as control. The results showed in panel 
a) highlight the presence of a band around 35 KDa in all samples. This probably corresponds 
to Atx3 fragments containing the N-terminal region with Myc tag. Interestingly, when Atx3 is 
co-expressed with linear M1-linked triUb, the intensity of the band at about 35 KDa is lower 
(see bands highlighted with red circle in Fig. 3.24a). These observations strongly suggest that 
triUb is able to obscure the catalytic site in Atx3 reducing its auto-cleavage propensity[99]. The 
reported results also allow to infer that a direct interaction exists in cell between Atx3 and M1-
linked triUb. 
In order to evaluate the behaviour of the over-expressed linear M1-linked triUb in the cell, 
western blot analysis was performed using anti-HA antibody for both, cells transfected with 
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only triUb and cells co-transfected using triUb and Atx3-Q14 and Atx3-Q55 (Fig.3.24b). Data 
do not show differences that could be related to the interaction between Atx3 and triUb. This is 
possible because linear M1-linked triUb is able in cell system to interact with several proteins, 
therefore it is difficult to assess a specific interaction with the only Atx3 variants. 
We also investigated by immunofluorescence assay the efficiency of transfection in HEK293 
for both Atx3-Q14 and Atx3-Q55. HEK293 cells were transfected for 48 hours using Atx3-Q14 
and Atx3-Q55 constructs and cells were stained using Anti-Myc and Anti-Atx3 antibodies, and 
DAPI for nuclei detection (Fig.3.25). As shown in figure both, Atx3-Q14 and Atx3-Q55 were 
mostly expressed in the cytoplasm, and partially in perinuclear region. Not significant differ-
ences were observed comparing the two Atx3 variants. Cell toxicity was not observed after 48 
hours transfection over expressing both Atx3-Q14 and Atx3-Q55. In the presented experiments 
it is not possible to distinguish the formation of aggregates or local accumulation of proteins. 
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Figure 3.25: Immunofluorescence assay of HEK293 transfected using both Myc-tagged_Atx3-Q14 and Myc-
tagged_Atx3-Q55 in pCI-Neo vector. The cells were fixed and immunostained with DAPI (blue), Anti-Myc and 
anti-Atx3 clone 1H9 (primary antibody) and AlexaFluor-488 (secondary antibody) (green). 
Immunofluorescence assay were also performed for HEK293 cells after co-transfection of 
Atx3-Q14 and linear M1-linked triUb, and after co-transfection of Atx3-Q55 and linear M1-
linked triUb (Fig. 3.26). On the basis of western blot analysis, these measurements add infor-
mation on the localization of triUb in cell in order to evaluate a possible interaction between 
Atx3 and triUb. The analysis revealed that exogenous triUb protein is present in the cytoplasm 
and co-localize with both Atx3 constructs. Although not significant evidence of interaction was 
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observed using this method, the presence of both proteins in the same cell region suggest the 
possibility of interaction between Atx3 and triUb. 
 
 
Figure 3.26: Immunofluorescence assay of HEK293 co-transfected with both Myc-tagged_Atx3-Q14 and Myc-
tagged_Atx3-Q55 and linear HA-tagged_M1-linked triUb. The cells were fixed and stained with DAPI (blue), 
Anti-Myc and anti-Atx3 (primary antibody), AlexaFluor-488 (secondary antibody) (green) AlexaFluor-800 (sec-
ondary antibody) (red). 
In this section, investigation on co-expression of Atx3 variants and linear M1-linked triUb in 
human cell model has been reported. Both, Atx3-Q14 and Atx3-Q55, and triUb were expressed 
in human cells. All proteins localize to the cytoplasm, and not cellular toxicity was observed 
after transfection, revealing that the constructs are suitable for in cell analysis. 
Aggregates formation was not detected in cells and results suggest a possible interaction be-
tween Atx3 and linear M1-linked triUb. Presented results are in line with observations in-vitro 
reported in chapter 3, where no significant differences were observed between the two Atx3-
Q14 and Atx3-Q54 variants. Furthermore, it was observed that Atx3 isoforms and linear M1-
linked triUb co-localize in cells, suggesting that is not possible to exclude an interaction. Even 
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if, the natural partner of Atx3 is K48-linked triUb, the findings observed using linear M1-linked 
triUb provide information for further investigations. 
3.4 Effect of K48-linked tri-Ubiquitin chains on Josephin domain aggrega-
tion process 
Above reported studies both in solution and in cells, evidence that selected model Atx3 variants 
present the same behaviour that does not depend on the polyQ tract but on the globular domain 
Jos.  According to results reported in the literature, Jos appears to be responsible for modulating 
the aggregation process of the full-length protein especially in the initial stages of the process. 
On the basis of this hypothesis, it was therefore decided to use Jos alone to evaluate in-vitro the 
possible protective role of polyUb on the Atx3 aggregation process. In vitro it was possible to 
use K48-linked triUb, that is recognized as target in the protein degradation process mediated 
by the proteasome in which Atx3 is also involved. In particular, K48-linked triUb were prepared 
by enzymatic reaction, and the effect of the interaction of these chains on the aggregation ki-
netics of Jos was investigated in-vitro. Several works have reported the aggregation analysis of 
the isolated Jos, confirming that Jos is able to aggregate under physiological condi-
tions[49][96][102][203]. Nicastro and co-workers, hypothesized that the physiological function 
of Atx3 could protect against aggregation, and coherently with this hypothesis they found that 
interaction between Jos and mUb had the effect of slowing down Jos aggregation without reach-
ing complete suppression. The aggregation pathway was modified in a way that final products 
were small amorphous aggregates[82]. Inspired by these encouraging data, an investigation on 
the effects of K48-linked triUb on Jos aggregation process was carried out in this thesis work. 
As the aim was to evaluate the effect of interaction between K48-linked triUb and Atx3 full-
length, an optimization of an efficient protocol to study the interaction between K48-linked 
triUb and Atx3 full-length proteins was also conducted. 
In this section, pilot measurements aimed at assessing the effect of the interaction between Jos 
and K48-linked triUb on the aggregation process are reported. 
Figure 3.27 shows the Rayleigh Scattering intensity measured at 440 nm (a), together with ThT 
fluorescence emission at 480 nm as a function of time (b) for Jos alone, and in complex with 
K48-linked triUb, in a 1:1 molar ratio. Experiments were performed in 20mM sodium phos-
phate buffer with 1mM TCEP, pH6.5, incubating at 50°C for 8 hours. Rayleigh scattering in-
tensity measured for Jos sample grows faster and reach higher values with respect to Jos in 
complex with triUb. Same trend is shown by ThT fluorescence, indicating that Jos samples 
forms aggregates with the same trend as the one observed for both Atx3 variants. This further 
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confirming previously described hypothesis that observed Atx3 aggregation processes were 
modulated by Jos. The plateau value for Jos domain is reached in about 2 hours. Jos in complex 
with K48 linked triUb, shows a slower kinetic leading to a lower plateau value. 
 
Figure 3.27: a) Comparison of Rayleigh scattering at 440nm as a function of time and b) ThT fluorescence emis-
sion at 480 nm as a function of time of 22 M Jos (red dots) and 22M Jos with k48-linked triUb chains (1:1 molar 
ratio) (green dots) with 26M ThT, in 20mM Na phosphate buffer with 1mM TCEP, pH 6.5 incubated at 50°C for 
8h. 
Results suggest that, in line with project hypothesis, the interaction with K48-linked triUb 
chains interfere with the aggregation pathway of Atx3. These encouraging data open the way 
to further studies in this direction. The experimental work was devoted in setting up in-vitro 
and in-cell experimental platform to analyse if and how the physiological function of Atx3 had 
an effect on aggregation processes in the light of using it to define new therapeutic strategy to 
slow down or inhibit Atx3 aggregation process in SCA3 patients. Further studies will be possi-
ble on the interactions between polyUb chains of different lengths with Atx3 highlighting the 
effect on protein stability aggregation propensity and mechanisms. Analogous studies are in 
progress with Atx3 with more than Q70 variant. 
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4 Conclusions 
This thesis was aimed at analysing the molecular mechanisms involved in the aberrant and 
pathogenic aggregation of Atx3 and the possible protective role of polyUb chains on this pro-
cess. This in the hypothesis that the interaction of Atx3 with its physiological partners may 
stabilise the native state reducing aberrant supramolecular assembly[103]. At this purpose, a 
clear understanding of molecular details of the interaction interfaces it is fundamental to gain 
information about the inducing stabilizing effects, and can provide useful clues for the design 
of synthetic peptide which can be efficiently used as drugs to treat the SCA3 pathology. Exper-
iments were performed in vitro and in cells in order to assess conditions and pivotal target 
mechanisms to analyse effects of polyUb chains on Atx3 variants selected as model of polyQ 
non-expanded and expanded proteins. A multiplexed experimental approach was developed 
based on protein engineering, which allows the preparation of high pure samples with suitable 
mutations, and biophysical methods. 
The first part of this work was focused on the analysis of conformational properties and aggre-
gation of Ub as a model of polyUb chain. This has the double purpose of defining the method-
ological approach for the study of aggregation processes and, at the same time, of analysing the 
conformational stability and structural changes of Ub in the experimental conditions chosen to 
investigate the possible protective role of polyUb on the Atx3 aggregation process. 
A combined use of UV-visible absorption spectroscopy, fluorescence spectroscopy, circular 
dichroism, and FTIR techniques was applied to analyse the effects of stress on Ub. In particular, 
it was found that, at high temperature or under agitation, Ub may form oligomeric aggregates 
with not amyloid features, following a process that does not involve significant changes at sec-
ondary structure level. In parallel, changes induced by UV stress were observed on Ub during 
its aggregation process highlighting light induced modifications, which occurs in experimental 
conditions commonly used to analyse conformational changes of proteins by means of intrinsic 
fluorescence signal. Importantly, UV-irradiation was found to lead to critical changes in emis-
sion profile of Ub, and in particular to the formation of a new band in the range 350–550 nm, 
which was assigned to oxidation products of tyrosine residues[133]. Results also clearly indi-
cated that the observed UV induced tyrosine oxidation occurs in proteins which lack in their 
sequence of tryptophan residues. The same spectral modifications were also observed for both 
Insulin and A(1-40)-amyloid samples grown under UV exposure, demonstrating that the sig-
nal attributed to tyrosine oxidation substantially overlaps (both in terms of spectral range and 
lifetime distribution) with the one attributed to intrinsic amyloid fluorescence. 
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These findings clearly represent a caveat about the specificity of the blue fluorescence peak 
measured for amyloids, especially when grown in conditions in which tyrosine residues may be 
oxidized. 
In the second part of the study, the experimental analysis of Atx3 aggregation processes both 
in cell and in vitro was performed to define the Atx3 aggregation mechanisms, and to investi-
gate on interactions to be used for the analysis of polyUb effect on Atx3 aggregation process. 
The study of Atx3 aggregation processes in vitro was performed using the experimental plat-
form optimised for the study of Ub. Particular care was dedicated in avoiding/minimising UV-
light exposure during the aggregation analysis steps. It is important to highlight that both Atx3-
Q14 and Atx3-Q54 variants used for in vitro studies were engineering with the point mutation 
C14A, responsible for inactivation of the catalytic activity of Atx3 towards polyUb chains, and 
for the auto-proteolytic property of Atx3. This choice was aimed at reducing the complexity of 
the aggregation process under observation avoiding the formation of polyQ fragments gener-
ated by self-cleavage that could promote heterogeneous nucleation mechanisms. This also al-
lowed to highlight the role of polyQ flanking domains in the regulation of Atx3 function and 
aggregation[102][197]. 
The results showed that both non-expanded Atx3-Q14 and expanded Atx3-Q54 variants follow, 
under selected experimental conditions, the same aggregation process. Notwithstanding the 
large difference in length of the polyQ tract, the two variants were found to form small amyloid 
like oligomers without involving nucleation mechanisms widely reported in other similar stud-
ies[94][95][196][197]. The observed monotonic growth of supramolecular assembly by means 
of light scattering and ThT fluorescence was paralleled by the progressive increase of intermo-
lecular -sheets highlighted by circular dichroism measurements. Different physic-chemical 
conditions were tested, which highlighted protein-solvent interactions, and in particular elec-
trostatic interactions as dominant in regulating the fibrils formation. The results are in line with 
recent literature which puts in evidence general laws underlying aggregation mechanisms of 
globular proteins, suggesting that in the presented experimental conditions the folded Jos plays 
a dominant role in Atx3. The comparison of experimental results with literature, suggests that 
isolating Atx3 aggregation mechanisms leaded by Jos are due both to the experimental condi-
tions, and to the selected Atx3 mutants with reduced self-cleavage propensity. 
Experiments in human cells were performed at the Basic & Clinical Neuroscience Department 
of King’s College of London, under the supervision of Prof. A. Pastore. The cell studies, as 
well as the in vitro studies, were focused at defining a suitable platform, and at revealing key 
interactions and suitable observables to analyse the effects of selected inhibitors on Atx3 tox-
icity in cellular environment. In particular, pilot experiments on the interaction between the two 
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Atx3 variants and polyUb were performed in HEK293 cells using recombinant linear M1-linked 
triUb as model. Over-expression of both solely Atx3-Q14 and solely Atx3-Q55 was also in-
duced in HEK293 cells to evaluate differences between the two variants in terms of cytotoxicity 
and ability to form aggregates in cellular environment. In line with in vitro studies, results in-
dicated that both Atx3 variants mainly localize in the cytoplasm, and do not form nuclear in-
clusions considered main hallmarks of cellular toxicity. 
A dedicated protocol to investigate the interaction between Atx3 and polyUb chains was also 
set up in cells system. Experiment were performed co-expressing Atx3 with recombinant linear 
M1-linked triUb in HEK293 cells. Promising results were obtained which revealed that both 
Atx3 and triUb co-localize in the cell cytoplasm, and that the auto-proteolytic propensity of 
Atx3 is clearly reduced in presence of co-expressed triUb. This evidence suggests an interaction 
between the two proteins, and a binding at the catalytic site of Atx3 responsible also for its 
auto-proteolytic activity. Although in the tested conditions aberrant aggregation of expanded 
Atx3 was not highlighted, the co-expression results give evidences of a possible interaction and 
pave the way to the setup analogous studies using Atx3 variants with longer polyQ expansion. 
Moreover, in cell studies revealed that Atx3 fragments are also physiologically generated, and 
that the size of these fragments is comparable to the size of the solely Jos. These results suggest 
that Jos, main actor of Atx3 catalytic function and key player in the early stage of Atx3 aggre-
gation process, is a valuable target to investigated the effect of possible modulators of aberrant 
aggregation. 
For this reason, Jos was the first target of polyUb interactions studies. This allowed to look at 
first only at simpler mechanisms occurring in the first step of Atx3 aggregation, which specifi-
cally involve Jos. In this way, other mechanisms related to the polyQ trait are excluded. 
In vitro pilot experiments were performed using K48-linked triUb chains, prepared by enzy-
matic reaction, and recombinant Jos, containing the same C14A point mutation used for the full 
length Atx3 variants. Experimental studies performed in analogous conditions as the one used 
for Atx3 variants, revealed that the aggregation of Jos in presence of K48-linked triUb chains 
is clearly inhibited. Indeed, both the aggregation rate and the amount of final amyloid aggre-
gates products resulted reduced, as indicated by combined scattering and ThT measurements. 
It is important to note that all the presented results highlight the role in the aberrant Atx3 ag-
gregation of fragments generated by auto-proteolytic activity of Atx3. In fact, under conditions 
in which this activity was inhibited or reduced, by temperature effect or because the presence 
of the point mutation C14A, no significant differences were observed between the two Atx3 
variants. 
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The presented results confirm the hypothesis that functional interaction may increase target 
protein stability and may reduce aberrant aggregation, encouraging studies on Atx3 variants 
which include the polyQ tract. These studies are in progress and will benefit of the large amount 
of evidences and protocols background produced till now. 
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ANNEX I 
His6-TEV-Jos1-182 C14A  
 
 
catcaccatcaccatcacgagaatctttattttcagggcgccatggagtccatcttccac 
H  H  H  H  H  H  E  N  L  Y  F  Q  G  A  M  E  S  I  F  H 
gagagacaagaaggctcacttgctgctcaacattgcctgaataacttattgcaaggagaa 
E  R  Q  E  G  S  L  A  A  Q  H  C  L  N  N  L  L  Q  G  E 
tattttagccctgtggaattatcctcaattgcacatcagctggatgaggaggagaggatg 
Y  F  S  P  V E  L  S  S  I  A  H  Q  L  D  E  E  E  R  M 
agaatggcagaaggaggagttactagtgaagattatcgcacgtttttacagcagccttct 
R  M  A  E  G G  V  T  S  E  D  Y  R  T  F  L  Q  Q  P  S 
ggaaatatggatgacgtggttttttctctattcaggttataagcaatgccttgagagtt 
G  N  M  D  D S  G  F  F  S  I  Q  V  I  S  N  A  L  R  V 
tggggtttagaactaatcctgttcaacagtccagagtatcagaggctcaggatcgatcct 
W  G  L  E  L  I  L  F  N  S  P  E  Y  Q  R  L  R  I  D  P 
ataaatgaaagatcatttatatgcaattataaggaacactggtttacagttagaagatta 
I  N  E  R  S F  I  C  N  Y  K  E  H  W  F  T  V  R  R  L 
ggaagacagtggtttacttgaattctctcttgacgggtccagaattaatatcagataca 
G  R  Q  W  F N  L  N  S  L  L  T  G  P  E  L  I  S  D  T 
tatcttgcacttttcttggctcaattacaacaggaaggttattctatatttgtcgttagg 
Y  L  A  L  F L  A  Q  L  Q  Q  E  G  Y  S  I  F  V  V  R 
ggtgatctgccagattgcgaagctgaccaactcctgcagatgattaggtag 
G  D  L  P  D C  E  A  D  Q  L  L  Q  M  I  R   
 
 
Jos1-182 C14A sequence 
 
 
      10         20         30         40         50         60  
MESIFHERQE GSLAAQHCLN NLLQGEYFSP VELSSIAHQL DEEERMRMAE GGVTSEDYRT  
 
        70         80         90        100        110        120  
FLQQPSGNMD DSGFFSIQVI SNALRVWGLE LILFNSPEYQ RLRIDPINER SFICNYKEHW  
 
       130        140        150        160        170        180  
FTVRRLGRQW FNLNSLLTGP ELISDTYLAL FLAQLQQEGY SIFVVRGDLP DCEADQLLQM  
 
 
IR  
  
 106 
  HisTag -TEV-Jos1-182 
C14A 
Jos1-182 C14A 
Number of amino acids  
196 182 
Molecular weight  
22889.68 21143.84 
Theoretical pI  
4.95 4.67 
Amino acid composi-
tion   
Ala (A)   9   4.6% 
Arg (R)  13   6.6% 
Asn (N)  10   5.1% 
Asp (D)   9   4.6% 
Cys (C)   3   1.5% 
Gln (Q)  15   7.7% 
Glu (E)  18   9.2% 
Gly (G)  12   6.1% 
His (H)  10   5.1% 
Ile (I)  11   5.6% 
Leu (L)  25  12.8% 
Lys (K)   1   0.5% 
Met (M)   5   2.6% 
Phe (F)  12   6.1% 
Pro (P)   6   3.1% 
Ser (S)  15   7.7% 
Thr (T)   5   2.6% 
Trp (W)   3   1.5% 
Tyr (Y)   7   3.6% 
Val (V)   7   3.6% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0%  
Ala (A)   8   4.4% 
Arg (R)  13   7.1% 
Asn (N)   9   4.9% 
Asp (D)   9   4.9% 
Cys (C)   3   1.6% 
Gln (Q)  14   7.7% 
Glu (E)  17   9.3% 
Gly (G)  11   6.0% 
His (H)   4   2.2% 
Ile (I)  11   6.0% 
Leu (L)  24  13.2% 
Lys (K)   1   0.5% 
Met (M)   5   2.7% 
Phe (F)  11   6.0% 
Pro (P)   6   3.3% 
Ser (S)  15   8.2% 
Thr (T)   5   2.7% 
Trp (W)   3   1.6% 
Tyr (Y)   6   3.3% 
Val (V)   7   3.8% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0%  
Total number of nega-
tively charged (Asp + 
Glu)  
27 26  
Total number of posi-
tively charged (Arg + 
Lys)   
14 14 
Ext. coefficient at 
280 nm      
(assuming all pairs 
of Cys residues form 
cysteines)   
27055 25565 
Abs 0.1% (=1 g/l) (as-
suming all pairs 
of Cys residues form 
cysteines)  
1.182 1.209 
Ext. coefficient at 
280 nm   
(assuming all Cys res-
idues are reduced)  
26930 25440 
Abs 0.1% (=1 g/l) (as-
suming all Cys resi-
dues are reduced)  1.177 1.203 
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MBP-His6-TEV-FL Atx3 C14A Q14 3UIMs Isoform V212 G310 
  
atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt 
M  K  I  E  E  G  K  L  V  I  W  I  N  G  D  K  G  Y  N  G 
ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat 
L  A  E  V  G  K  K  F  E  K  D  T  G  I  K  V  T  V  E  H 
ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt 
P  D  K  L  E  E  K  F  P  Q  V  A  A  T  G  D  G  P  D  I 
atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc 
I  F  W  A  H  D  R  F  G  G  Y  A  Q  S  G  L  L  A  E  I 
accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac 
T  P  D  K  A  F  Q  D  K  L  Y  P  F  T  W  D  A  V  R  Y 
aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa 
N  G  K  L  I  A  Y  P  I  A  V  E  A  L  S  L  I  Y  N  K 
gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg 
D  L  L  P  N  P  P  K  T  W  E  E  I  P  A  L  D  K  E  L 
aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg 
K  A  K  G  K  S  A  L  M  F  N  L  Q  E  P  Y  F  T  W  P 
ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa 
L  I  A  A  D  G  G  Y  A  F  K  Y  E  N  G  K  Y  D  I  K 
gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt 
D  V  G  V  D  N  A  G  A  K  A  G  L  T  F  L  V  D  L  I 
aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa 
K  N  K  H  M  N  A  D  T  D  Y  S  I  A  E  A  A  F  N  K 
ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa 
G  E  T  A  M  T  I  N  G  P  W  A  W  S  N  I  D  T  S  K 
gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt 
V  N  Y  G  V  T  V  L  P  T  F  K  G  Q  P  S  K  P  F  V 
ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc 
G  V  L  S  A  G  I  N  A  A  S  P  N  K  E  L  A  K  E  F 
ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg 
L  E  N  Y  L  L  T  D  E  G  L  E  A  V  N  K  D  K  P  L 
ggtgccgtagcgctgaagtcttacgaggaagagttggtgaaagatccgcgtattgccgcc 
G  A  V  A  L  K  S  Y  E  E  E  L  V  K  D  P  R  I  A  A 
actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc 
T  M  E  N  A  Q  K  G  E  I  M  P  N  I  P  Q  M  S  A  F 
tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa 
W  Y  A  V  R  T  A  V  I  N  A  A  S  G  R  Q  T  V  D  E 
gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac 
A  L  K  D  A  Q  T  N  S  S  S  N  N  N  N  N  N  N  N  N 
aacctcgggatcgagggaaggatttcacatcaccatcatcaccacgaaaacctgtacttt 
N  L  G  I  E  G  R  I  S  H  H  H  H  H  H  E  N  L  Y  F 
cagggcatggagtccatcttccacgagaaacaagaaggctcacttgctgctcaacattgc 
Q  G  M  E  S  I  F  H  E  K  Q  E  G  S  L  A  A  Q  H  C 
ctgaataacttattgcaaggagaatattttagccctgtggaattatcctcaattgcacat 
L  N  N  L  L  Q  G  E  Y  F  S  P  V  E  L  S  S  I  A  H 
cagctggatgaggaggagaggatgagaatggcagaaggaggagttactagtgaagattat 
Q  L  D  E  E  E  R  M  R  M  A  E  G  G  V  T  S  E  D  Y 
cgcacgtttttacagcagccttctggaaatatggatgacagtggttttttctctattcag 
R  T  F  L  Q  Q  P  S  G  N  M  D  D  S  G  F  F  S  I  Q 
gttataagcaatgccttgaaagtttggggtttagaactaatcctgttcaacagtccagag 
V  I  S  N  A  L  K  V  W  G  L  E  L  I  L  F  N  S  P  E 
tatcagaggctcaggatcgatcctataaatgaaagatcatttatatgcaattataaggaa 
Y  Q  R  L  R  I  D  P  I  N  E  R  S  F  I  C  N  Y  K  E 
cactggtttacagttagaaaattaggaaaacagtggtttaacttgaattctctcttgacg 
H  W  F  T  V  R  K  L  G  K  Q  W  F  N  L  N  S  L  L  T 
ggtccagaattaatatcagatacatatcttgcacttttcttggctcaattacaacaggaa 
G  P  E  L  I  S  D  T  Y  L  A  L  F  L  A  Q  L  Q  Q  E 
ggttattctatatttgtcgttaagggtgatctgccagattgcgaagctgaccaactccta 
G  Y  S  I  F  V  V  K  G  D  L  P  D  C  E  A  D  Q  L  L 
cagatgattagggtccaacagatgcatcgaccaaaacttattggagaagaattagcacaa 
Q  M  I  R  V  Q  Q  M  H  R  P  K  L  I  G  E  E  L  A  Q 
ctaaaagagcaaagagtccataaaacagacctggaacgagtgttagaagcaaatgatggc 
 108 
L  K  E  Q  R  V  H  K  T  D  L  E  R  V  L  E  A  N  D  G 
tcaggaatgttagacgaagatgaggaggatttgcagagggctctggcactaagtcgccaa 
S  G  M  L  D  E  D  E  E  D  L  Q  R  A  L  A  L  S  R  Q 
gaaattgacatggaagatgaggaagcagatctccgcagggctattcagctaagtatgcaa 
E  I  D  M  E  D  E  E  A  D  L  R  R  A  I  Q  L  S  M  Q 
ggtagttccagaaacatatctcaagatatgacacagacatcaggtacaaatcttacttca 
G  S  S  R  N  I  S  Q  D  M  T  Q  T  S  G  T  N  L  T  S 
gaagagcttcggaagagacgagaagcctactttgaaaaacagcagcaaaagcagcaacag 
E  E  L  R  K  R  R  E  A  Y  F  E  K  Q  Q  Q  K  Q  Q  Q 
cagcagcagcagcagcagcagggggacctatcaggacagagttcacatccatgtgaaagg 
Q  Q  Q  Q  Q  Q  Q  G  D  L  S  G  Q  S  S  H  P  C  E  R   
ccagccaccagttcaggagcacttgggagtgatctaggtgatgctatgagtgaagaagca 
P  A  T  S  S  G  A  L  G  S  D  L  G  D  A  M  S  E  E  D 
atgcttcaggcagctgtgaccatgtctttagaaactgtcagaaatgatttgaaaacagaa 
M  L  Q  A  A  V  T  M  S  L  E  T  V  R  N  D  L  K  T  E 
ggaaaaaaataa 
G  K  K  - 
 
 
 
Atx3 C14A Q14 3UIMs Isoform V212;G310 after TEV cleavage 
 
     10         20         30         40         50         60  
GMESIFHEKQ EGSLCAQHCL NNLLQGEYFS PVELSSIAHQ LDEEERMRMA EGGVTSEDYR  
 
        70         80         90        100        110        120  
TFLQQPSGNM DDSGFFSIQV ISNALKVWGL ELILFNSPEY QRLRIDPINE RSFICNYKEH  
 
       130        140        150        160        170        180  
WFTVRKLGKQ WFNLNSLLTG PELISDTYLA LFLAQLQQEG YSIFVVKGDL PDCEADQLLQ  
 
       190        200        210        220        230        240  
MIRVQQMHRP KLIGEELAQL KEQRVHKTDL ERVLEANDGS GMLDEDEEDL QRALALSRQE  
 
       250        260        270        280        290        300  
IDMEDEEADL RRAIQLSMQG SSRNISQDMT QTSGTNLTSE ELRKRREAYF EKQQQKQQQQ  
 
       310        320        330        340        350        360  
QQQQQQGDLS GQSSHPCERP ATSSGALGSD LGDAMSEEDM LQAAVTMSLE TVRNDLKTEG  
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  MBP-HisTag -TEV- Atx3 
C14A Q14 3UIMs 
Atx3 C14A Q14 3UIMs 
Number of amino acids  
763 362 
Molecular weight  
85617.06 41307.09  
Theoretical pI  
4.95 4.69  
Amino acid composition   Ala (A)  62   8.1% 
Arg (R)  27   3.5% 
Asn (N)  46   6.0% 
Asp (D)  47   6.2% 
Cys (C)   5   0.7% 
Gln (Q)  49   6.4% 
Glu (E)  67   8.8% 
Gly (G)  54   7.1% 
His (H)  16   2.1% 
Ile (I)  39   5.1% 
Leu (L)  75   9.8% 
Lys (K)  51   6.7% 
Met (M)  20   2.6% 
Phe (F)  28   3.7% 
Pro (P)  30   3.9% 
Ser (S)  47   6.2% 
Thr (T)  33   4.3% 
Trp (W)  11   1.4% 
Tyr (Y)  23   3.0% 
Val (V)  33   4.3% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0%  
Ala (A)  19   5.2% 
Arg (R)  21   5.8% 
Asn (N)  13   3.6% 
Asp (D)  23   6.4% 
Cys (C)   5   1.4% 
Gln (Q)  39  10.8% 
Glu (E)  38  10.5% 
Gly (G)  23   6.4% 
His (H)   7   1.9% 
Ile (I)  15   4.1% 
Leu (L)  43  11.9% 
Lys (K)  15   4.1% 
Met (M)  13   3.6% 
Phe (F)  12   3.3% 
Pro (P)   9   2.5% 
Ser (S)  31   8.6% 
Thr (T)  14   3.9% 
Trp (W)   3   0.8% 
Tyr (Y)   7   1.9% 
Val (V)  12   3.3% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
  
Total number of nega-
tively charged (Asp + 
Glu)  
114 61  
Total number of posi-
tively charged (Arg + 
Lys)   
78 36 
Ext. coefficient at 280 
nm      
(assuming all pairs 
of Cys residues form 
cysteines)   
95020  27180  
Abs 0.1% (=1 g/l) (as-
suming all pairs 
of Cys residues form 
cysteines)  
1.110 0.658 
Ext. coefficient at 280 
nm   
(assuming all Cys resi-
dues are reduced)  
94770  26930  
Abs 0.1% (=1 g/l) (as-
suming all Cys residues 
are reduced)  1.107 0.652 
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MBP-His6-TEV-FL Atx3 C14A Q54 3UIMs Isoform V212 G310 
 
atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt 
M  K  I  E  E  G  K  L  V  I  W  I  N  G  D  K  G  Y  N  G 
ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat 
L  A  E  V  G  K  K  F  E  K  D  T  G  I  K  V  T  V  E  H 
ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt 
P  D  K  L  E  E  K  F  P  Q  V  A  A  T  G  D  G  P  D  I 
atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc 
I  F  W  A  H  D  R  F  G  G  Y  A  Q  S  G  L  L  A  E  I 
accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac 
T  P  D  K  A  F  Q  D  K  L  Y  P  F  T  W  D  A  V  R  Y 
aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa 
N  G  K  L  I  A  Y  P  I  A  V  E  A  L  S  L  I  Y  N  K 
gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg 
D  L  L  P  N  P  P  K  T  W  E  E  I  P  A  L  D  K  E  L 
aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg 
K  A  K  G  K  S  A  L  M  F  N  L  Q  E  P  Y  F  T  W  P 
ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa 
L  I  A  A  D  G  G  Y  A  F  K  Y  E  N  G  K  Y  D  I  K 
gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt 
D  V  G  V  D  N  A  G  A  K  A  G  L  T  F  L  V  D  L  I 
aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa 
K  N  K  H  M  N  A  D  T  D  Y  S  I  A  E  A  A  F  N  K 
ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa 
G  E  T  A  M  T  I  N  G  P  W  A  W  S  N  I  D  T  S  K 
gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt 
V  N  Y  G  V  T  V  L  P  T  F  K  G  Q  P  S  K  P  F  V 
ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc 
G  V  L  S  A  G  I  N  A  A  S  P  N  K  E  L  A  K  E  F 
ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg 
L  E  N  Y  L  L  T  D  E  G  L  E  A  V  N  K  D  K  P  L 
ggtgccgtagcgctgaagtcttacgaggaagagttggtgaaagatccgcgtattgccgcc 
G  A  V  A  L  K  S  Y  E  E  E  L  V  K  D  P  R  I  A  A 
actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc 
T  M  E  N  A  Q  K  G  E  I  M  P  N  I  P  Q  M  S  A  F 
tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa 
W  Y  A  V  R  T  A  V  I  N  A  A  S  G  R  Q  T  V  D  E 
gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac 
A  L  K  D  A  Q  T  N  S  S  S  N  N  N  N  N  N  N  N  N 
aacctcgggatcgagggaaggatttcacatcaccatcatcaccacgaaaacctgtacttt 
N  L  G  I  E  G  R  I  S  H  H  H  H  H  H  E  N  L  Y  F 
cagggcatggagtccatcttccacgagaaacaagaaggctcacttgctgctcaacattgc 
Q  G  M  E  S  I  F  H  E  K  Q  E  G  S  L  A  A  Q  H  C 
ctgaataacttattgcaaggagaatattttagccctgtggaattatcctcaattgcacat 
L  N  N  L  L  Q  G  E  Y  F  S  P  V  E  L  S  S  I  A  H 
cagctggatgaggaggagaggatgagaatggcagaaggaggagttactagtgaagattat 
Q  L  D  E  E  E  R  M  R  M  A  E  G  G  V  T  S  E  D  Y 
cgcacgtttttacagcagccttctggaaatatggatgacagtggttttttctctattcag 
R  T  F  L  Q  Q  P  S  G  N  M  D  D  S  G  F  F  S  I  Q 
gttataagcaatgccttgaaagtttggggtttagaactaatcctgttcaacagtccagag 
V  I  S  N  A  L  K  V  W  G  L  E  L  I  L  F  N  S  P  E 
tatcagaggctcaggatcgatcctataaatgaaagatcatttatatgcaattataaggaa 
Y  Q  R  L  R  I  D  P  I  N  E  R  S  F  I  C  N  Y  K  E 
cactggtttacagttagaaaattaggaaaacagtggtttaacttgaattctctcttgacg 
H  W  F  T  V  R  K  L  G  K  Q  W  F  N  L  N  S  L  L  T 
ggtccagaattaatatcagatacatatcttgcacttttcttggctcaattacaacaggaa 
G  P  E  L  I  S  D  T  Y  L  A  L  F  L  A  Q  L  Q  Q  E 
ggttattctatatttgtcgttaagggtgatctgccagattgcgaagctgaccaactccta 
G  Y  S  I  F  V  V  K  G  D  L  P  D  C  E  A  D  Q  L  L 
cagatgattagggtccaacagatgcatcgaccaaaacttattggagaagaattagcacaa 
Q  M  I  R  V  Q  Q  M  H  R  P  K  L  I  G  E  E  L  A  Q 
ctaaaagagcaaagagtccataaaacagacctggaacgagtgttagaagcaaatgatggc 
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L  K  E  Q  R  V  H  K  T  D  L  E  R  V  L  E  A  N  D  G 
tcaggaatgttagacgaagatgaggaggatttgcagagggctctggcactaagtcgccaa 
S  G  M  L  D  E  D  E  E  D  L  Q  R  A  L  A  L  S  R  Q 
gaaattgacatggaagatgaggaagcagatctccgcagggctattcagctaagtatgcaa 
E  I  D  M  E  D  E  E  A  D  L  R  R  A  I  Q  L  S  M  Q 
ggtagttccagaaacatatctcaagatatgacacagacatcaggtacaaatcttacttca 
G  S  S  R  N  I  S  Q  D  M  T  Q  T  S  G  T  N  L  T  S 
gaagagcttcggaagagacgagaagcctactttgaaaaacagcagcaaaagcagcaacag 
E  E  L  R  K  R  R  E  A  Y  F  E  K  Q  Q  Q  K  Q  Q  Q 
cagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 
Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q 
cagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag 
Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q 
cagcagcagcagcagcagcagggggacctatcaggacagagttcacatccatgtgaaagg 
Q  Q  Q  Q  Q  Q  Q  G  D  L  S  G  Q  S  S  H  P  C  E  R 
ccagccaccagttcaggagcacttgggagtgatctaggtgatgctatgagtgaagaagac 
P  A  T  S  S  G  A  L  G  S  D  L  G  D  A  M  S  E  E  D 
atgcttcaggcagctgtgaccatgtctttagaaactgtcagaaatgatttgaaaacagaa 
M  L  Q  A  A  V  T  M  S  L  E  T  V  R  N  D  L  K  T  E 
ggaaaaaaataa 
G  K  K  - 
 
 
 
Atx3 C14A Q54 3UIMs after TEV cleavage 
  
      10         20         30         40         50         60   
GMESIFHEKQ EGSLAAQHCL NNLLQGEYFS PVELSSIAHQ LDEEERMRMA EGGVTSEDYR   
  
        70         80         90        100        110        120   
TFLQQPSGNM DDSGFFSIQV ISNALKVWGL ELILFNSPEY QRLRIDPINE RSFICNYKEH   
  
       130        140        150        160        170        180   
WFTVRKLGKQ WFNLNSLLTG PELISDTYLA LFLAQLQQEG YSIFVVKGDL PDCEADQLLQ   
  
       190        200        210        220        230        240   
MIRVQQMHRP KLIGEELAQL KEQRVHKTDL ERVLEANDGS GMLDEDEEDL QRALALSRQE   
  
       250        260        270        280        290        300   
IDMEDEEADL RRAIQLSMQG SSRNISQDMT QTSGTNLTSE ELRKRREAYF EKQQQKQQQQ   
  
       310        320        330        340        350        360   
QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQQQQQ QQQQQQGDLS GQSSHPCERP   
  
       370        380        390        400   
ATSSGALGSD LGDAMSEEDM LQAAVTMSLE TVRNDLKTEG KK  
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  MBP-HisTag -TEV- 
Atx3 C14A Q54 3UIMs 
Atx3 C14A Q54 3UIMs 
Number of amino acids  
803 402 
Molecular weight  
90710.23  46400.26  
Theoretical pI  
4.95  4.69  
Amino acid composition   Ala (A)  63  7.8% 
Arg (R)  27  3.4% 
Asn (N)  46  5.7% 
Asp (D)  47  5.9% 
Cys (C)   4  0.5% 
Gln (Q)  89 11.1% 
Glu (E)  67  8.3% 
Gly (G)  54  6.7% 
His (H)  16  2.0% 
Ile (I)  39  4.9% 
Leu (L)  75  9.3% 
Lys (K)  51  6.4% 
Met (M)  20  2.5% 
Phe (F)  28  3.5% 
Pro (P)  30  3.7% 
Ser (S)  47  5.9% 
Thr (T)  33  4.1% 
Trp (W)  11  1.4% 
Tyr (Y)  23  2.9% 
Val (V)  33  4.1% 
Pyl (O)   0  0.0% 
Sec (U)   0  0.0% 
Ala (A)  20  5.0% 
Arg (R)  21  5.2% 
Asn (N)  13  3.2% 
Asp (D)  23  5.7% 
Cys (C)   4  1.0% 
Gln (Q)  79 19.7% 
Glu (E)  38  9.5% 
Gly (G)  23  5.7% 
His (H)   7  1.7% 
Ile (I)  15  3.7% 
Leu (L)  43 10.7% 
Lys (K)  15  3.7% 
Met (M)  13  3.2% 
Phe (F)  12  3.0% 
Pro (P)   9  2.2% 
Ser (S)  31  7.7% 
Thr (T)  14  3.5% 
Trp (W)   3  0.7% 
Tyr (Y)   7  1.7% 
Val (V)  12  3.0% 
Pyl (O)   0  0.0% 
Sec (U)   0  0.0% 
Total number of nega-
tively charged (Asp + 
Glu)  
114 61 
Total number of posi-
tively charged (Arg + 
Lys)   
78 36 
Ext. coefficient at 280 
nm      
(assuming all pairs 
of Cys residues form 
cysteines)   
95020  27180  
Abs 0.1% (=1 g/l) (as-
suming all pairs 
of Cys residues form 
cysteines)  
1.048  0.586  
Ext. coefficient at 280 
nm   
(assuming all Cys resi-
dues are reduced)  
94770  26930  
Abs 0.1% (=1 g/l) (as-
suming all Cys residues 
are reduced)  1.045  0.580  
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ANNEX II 
pCI-Neo Vector Multiple Cloning Region (from Promega): 
 
 
 
Figure T7 and T3 RNA polymerase promoters and multiple cloning region sequence of the 
pCI-Neo Vector. The sequence shown corresponds to RNA synthesized by T7 RNA polymerase 
and is complementary to RNA synthesized by T3 RNA polymerase. The strand shown is the 
same as the ssDNA produced by the vector. 
 
pCI-Neo Vector Circle Map (from Promega): 
 
pCI-Neo Sequence Reference Points: 
CMV immediate-early enhancer/promoter region 1–750 
Chimeric intron 890–1022 
 114 
T7-EEV sequencing primer binding region 1053–1074 
T7 RNA polymerase promoter (–17 to +2) 1067–1085 
Multiple cloning region 1085–1137 
T3 RNA polymerase promoter (–17 to +3) 1140–1158 
SV40 late polyadenylation signal 1167–1388 
Phage f1 region 1483–1938 
SV40 enhancer and early promoter 2000–2418 
SV40 minimum origin of replication 2316–2381 
Coding region of neomycin phosphotransferase 2463–3257 
Synthetic polyadenylation signal 3321–3369 
β-lactamase (Ampr) coding region 3780–4640 
 
pTet-ONE vector Circle Map (from Clontech® Laboratories, Inc): 
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